<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Delivery of inhaled medication in adults</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Delivery of inhaled medication in adults</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Delivery of inhaled medication in adults</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Dean Hess, RRT, PhD, FAARC, FCCM</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rajiv Dhand, MD, FCCP, FACP, FAARC, FRSM, ATSF</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Anne E Dixon, BM, BCh</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Paul Dieffenbach, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 06, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The delivery of therapeutic aerosols is an important component of treatment for many respiratory disorders. The advantages of aerosolized therapy include delivery of medication directly to the site of action, potentially faster onset of action, and reduced systemic availability to minimize adverse effects of the medication.</p><p>The types and function of devices available for delivery of therapeutic aerosols are reviewed here. The education of patients regarding optimal inhaler technique and the role of these medications in the management of asthma and chronic obstructive pulmonary disease (COPD) are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/559.html" rel="external">"The use of inhaler devices in adults"</a> and  <a class="medical medical_review" href="/z/d/html/5738.html" rel="external">"The use of inhaler devices in children"</a> and  <a class="medical medical_review" href="/z/d/html/547.html" rel="external">"An overview of asthma management"</a> and  <a class="medical medical_review" href="/z/d/html/1447.html" rel="external">"Stable COPD: Initial pharmacologic management"</a> and  <a class="medical medical_review" href="/z/d/html/1461.html" rel="external">"COPD exacerbations: Management"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">OVERVIEW</span><span class="headingEndMark"> — </span>The principal types of devices used to generate therapeutic aerosols are pressurized metered dose inhalers (pMDIs), dry powder inhalers (DPIs), soft mist inhalers (SMIs), and nebulizers [<a href="#rid1">1-3</a>]. pMDIs may be used with or without a spacer/valved holding chamber. Some breath actuated pMDIs (eg, QVAR Redihaler and others available outside the United States) overcome the problem of incoordination between actuation and inhalation that is commonly observed with pMDIs. Among nebulizers, three basic types have been developed, jet (also known as pneumatic), ultrasonic, and mesh. Jet nebulizer systems are typically less portable than pMDIs and DPIs. In the past, nebulizers were considered more expensive delivery devices; however, in some settings, hydrofluoroalkane (HFA) formulations of pMDIs, SMIs, and DPIs may be more expensive than the solutions used in a nebulizer. </p><p>Inhalation (or aerosol) therapy can be employed with a range of medications and devices. Examples include:</p><p class="bulletIndent1"><span class="glyph">●</span>Inhaled beta agonist and muscarinic antagonist (anticholinergic) bronchodilators for chronic obstructive lung diseases (eg, asthma, COPD, bronchiectasis, bronchiolitis)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Inhaled glucocorticoids (also called inhaled corticosteroids or ICS) for asthma, eosinophilic bronchitis, and COPD</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Inhaled antibiotics for prevention of Pneumocystis pneumonia and treatment of respiratory syncytial virus, cystic fibrosis, and bronchiectasis</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Airway secretion modifying agents for cystic fibrosis</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Inhaled pulmonary vasodilators for pulmonary hypertension [<a href="#rid4">4</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Aerosol delivery of drugs (eg, opiates, insulin, levodopa, <a class="drug drug_general" data-topicid="9576" href="/z/d/drug information/9576.html" rel="external">loxapine</a>) may be used to treat some nonrespiratory diseases [<a href="#rid5">5-7</a>]</p><p></p><p>The advantages and disadvantages to each of the different types of aerosol delivery devices are listed in the table  (<a class="graphic graphic_table graphicRef71527" href="/z/d/graphic/71527.html" rel="external">table 1</a>). The available evidence from systematic reviews and meta-analyses suggests equivalence among nebulizers, pMDIs, and DPIs for delivery of beta agonists and glucocorticoids when used correctly [<a href="#rid8">8-15</a>]. Thus, for spontaneously breathing patients without a tracheostomy, the selection of an aerosol delivery device is usually based upon the preference and convenience of the clinician and patient, the ability of the patient to use the device correctly, the durability of the device, and the cost of therapy rather than a clear superiority of one device over another [<a href="#rid8">8</a>]. However, in some situations, choice of device is determined by drug formulation, as some formulations require a particular delivery device, and patient interface factors, such as presence of a tracheotomy or mechanical ventilation.</p><p>The proper technique for using aerosol devices varies from one device to another and is a key component of optimal drug deposition and the desired therapeutic response. Understanding the correct use of aerosol delivery devices and providing patient education is a shared responsibility among all health care professionals participating in asthma or COPD management (eg, physicians, respiratory therapists, nurses, and pharmacists) [<a href="#rid16">16</a>]. Preferably, patients should use one type of inhaler device (either pMDIs, DPIs, or SMIs) for both reliever and maintenance therapy [<a href="#rid17">17-19</a>]. Inhaler technique for pMDIs and DPIs is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/559.html" rel="external">"The use of inhaler devices in adults"</a> and  <a class="medical medical_review" href="/z/d/html/5738.html" rel="external">"The use of inhaler devices in children"</a>.)</p><p>All the commonly employed aerosol delivery devices can be used to deliver medication to spontaneously breathing patients who can inhale orally. Only nebulizers and pMDIs can be used in patients who are intubated or have a tracheostomy; DPIs are not designed for use in these patients and adapters to connect SMIs in the ventilator circuit are not commercially available. Only nebulizers can be used with high flow nasal cannula. </p><p class="headingAnchor" id="H339815"><span class="h1">PRESSURIZED METERED DOSE INHALERS (pMDI)</span><span class="headingEndMark"> — </span>A pMDI consists of a pressurized canister, a metering valve and stem, and a mouthpiece actuator  (<a class="graphic graphic_picture graphicRef62613" href="/z/d/graphic/62613.html" rel="external">picture 1</a>) [<a href="#rid20">20</a>]. The canister contains the drug suspended in a pressurized mixture of propellants, surfactants, preservatives, flavoring agents, and dispersal agents. The propellent is hydrofluoroalkane (HFA) [<a href="#rid21">21</a>]. </p><p>The medication-propellant mixture is released from the pMDI canister through the metering valve and stem into an actuator boot. Lung deposition ranges between 10 and 40 percent of the nominal dose in adults and is very technique-dependent. Some newer generation HFA-pMDIs have been formulated as ethanolic solutions, and they produce a finer aerosol spray with greater peripheral lung deposition and improved efficacy of drug delivery [<a href="#rid22">22,23</a>]. (See  <a class="medical medical_review" href="/z/d/html/559.html" rel="external">"The use of inhaler devices in adults", section on 'Pressurized metered dose inhalers'</a>.)</p><p>Examples of medications available in a pMDI include short-acting beta agonists (SABAs) and long-acting beta agonists (LABAs)  (<a class="graphic graphic_table graphicRef72467" href="/z/d/graphic/72467.html" rel="external">table 2</a>), <a class="drug drug_general" data-topicid="8570" href="/z/d/drug information/8570.html" rel="external">ipratropium</a>, a number of ICS alone and in combination with a LABA, and a triple combination with ICS-long-acting antimuscarinic agent (LAMA)-LABA  (<a class="graphic graphic_table graphicRef78011" href="/z/d/graphic/78011.html" rel="external">table 3</a> and <a class="graphic graphic_table graphicRef68143" href="/z/d/graphic/68143.html" rel="external">table 4</a> and <a class="graphic graphic_table graphicRef116691" href="/z/d/graphic/116691.html" rel="external">table 5</a> and <a class="graphic graphic_table graphicRef122859" href="/z/d/graphic/122859.html" rel="external">table 6</a>). </p><p>New pMDI technology incorporates micronized drug crystals that are co-suspended with porous phospholipid particles in the HFA propellant. The drug crystals form strong associations with the porous phospholipid particles, and the drug-to-porous-particle ratios employed minimize drug-drug interactions for multi-drug combinations within a single inhaler. Unlike conventional HFA pMDIs, no additional excipients, such as co-solvents or suspension stabilizers, are needed. This co-suspension technology was used in the development of a LAMA/LABA fixed-dose combination of <a class="drug drug_general" data-topicid="107880" href="/z/d/drug information/107880.html" rel="external">glycopyrrolate-formoterol</a> (Bevespi) and a triple combination of <a class="drug drug_general" data-topicid="129094" href="/z/d/drug information/129094.html" rel="external">budesonide-glycopyrrolate-formoterol</a> (Breztri) in a pMDI  (<a class="graphic graphic_table graphicRef116691" href="/z/d/graphic/116691.html" rel="external">table 5</a> and <a class="graphic graphic_table graphicRef122859" href="/z/d/graphic/122859.html" rel="external">table 6</a>)[<a href="#rid24">24</a>]. </p><p>The correct techniques for priming and using a pMDI, cleaning the actuator, determining when the canister is empty, and deciding when to use a spacer or chamber device are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/559.html" rel="external">"The use of inhaler devices in adults"</a> and  <a class="medical medical_review" href="/z/d/html/5738.html" rel="external">"The use of inhaler devices in children"</a> and  <a class="medical medical_patient" href="/z/d/html/369.html" rel="external">"Patient education: Inhaler techniques in adults (Beyond the Basics)"</a>.)</p><p>Difficulty precisely coordinating device actuation with inhalation leads to poor drug delivery, suboptimal disease control, and increased inhaler use [<a href="#rid25">25</a>]. Such problems might be overcome by employing a spacer/valved holding chamber or breath-actuated pMDI. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Spacer or valved holding chamber</strong> – A pMDI can be used with a spacer or valved holding chamber (VHC) to overcome problems related to incoordination between actuation and inhalation  (<a class="graphic graphic_picture graphicRef58957" href="/z/d/graphic/58957.html" rel="external">picture 2</a>). Spacer devices employ three basic designs: the open tube, the reservoir or VHC, and the reverse-flow design, in which the pMDI, placed close to the mouth, is fired in the direction away from the patient; adding a one-way valve creates a VHC. They can be used with a mouthpiece or mask, and anti-static devices reduce aerosol losses within the device. The use of these devices to improve aerosol delivery is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/559.html" rel="external">"The use of inhaler devices in adults", section on 'Spacers and holding chambers'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Breath-actuated inhalers</strong> – Breath-actuated pMDI can help overcome problems with coordination of device actuation with inhalation. The efficacy of breath-actuated pMDIs matches the results with pMDIs in patients who are able to use pMDIs effectively [<a href="#rid26">26</a>]. However, in patients with incoordination of inhalation with device actuation, breath-actuated inhalers can improve efficacy of drug responses [<a href="#rid27">27</a>]. The breath-actuated pMDI for <a class="drug drug_general" data-topicid="9068" href="/z/d/drug information/9068.html" rel="external">beclomethasone</a> (QVAR RediHaler, available in the United States) does not need to be shaken or primed, but it cannot be used with a spacer or VHC.</p><p></p><p class="headingAnchor" id="H339674"><span class="h1">DRY POWDER INHALERS (DPI)</span><span class="headingEndMark"> — </span>Dry powder inhalers (DPIs) create medication aerosols by drawing air through a dose of powdered medication  (<a class="graphic graphic_picture graphicRef57922" href="/z/d/graphic/57922.html" rel="external">picture 3</a>) [<a href="#rid28">28-30</a>]. DPIs vary in the use of carrier molecules, internal resistance to airflow, threshold inspiratory flow needed for deaggregation of powder, particle size, and susceptibility to clumping in high ambient humidity. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Carrier molecules</strong> – The micronized particles are either in the form of loose aggregates or they are bound to larger carrier particles (usually lactose or glucose). To facilitate deposition in the lungs, drug particles are deagglomerated (dispersed) during inhalation. In DPIs that contain drug particles blended with carrier lactose particles, turbulent energy created in the inhalation channel of the DPI by the interaction of inspiratory airflow with the resistance of the DPI dissociates the drug particles from the carrier particles. This turbulent energy produces a pressure change that breaks up (deaggregates) the formulation and entrains the deaggregated drug particles in the inspiratory airflow [<a href="#rid31">31</a>]. The magnitude of the pressure change depends on the strength of the respiratory muscles, the degree of patient effort (ie, the force of the inhalation), and to a much lesser extent on disease severity [<a href="#rid32">32</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Internal resistance to airflow</strong> – The internal resistance to airflow varies among DPIs over a broad range [<a href="#rid2">2</a>]. The turbulent energy created during inhalation is the product of the patient’s inhalation flow multiplied by the DPI’s resistance [<a href="#rid31">31</a>]. Thus, a DPI with a high resistance will require a lower inhalation flow to achieve a similar pressure difference, than a DPI with a lower resistance [<a href="#rid32">32,33</a>]. In general, as the patient's inspiratory effort increases, the flow through a given device increases and this translates into more effective aerosolization, greater particle dispersal (ie, reduced agglomeration of the particles), and a greater fine particle dose (FPD) [<a href="#rid33">33</a>]. DPIs with a high resistance tend to produce greater lung deposition than those with a lower resistance [<a href="#rid31">31,32</a>], but the clinical significance of this is not known. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Threshold inspiratory flow</strong> – For each DPI there is a minimum turbulent energy that must be achieved for sufficient deaggregation of the powder during an inhalation [<a href="#rid34">34</a>]. Young (pre-school) children with asthma [<a href="#rid35">35</a>] and patients with COPD [<a href="#rid36">36</a>] may have problems achieving minimum flows through some DPIs, especially if inhalation flow is reduced during exacerbations [<a href="#rid37">37</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Particle size</strong> – DPIs produce aerosols in which most of the drug particles are in the respirable range; however, the distribution of particle sizes differs significantly among the various DPIs. These devices are either single-dose or multiple-dose. Multi-dose DPIs either contain a bulk formulation in a reservoir that is metered by the patient during use, or they contain pre-metered factory dispensed doses packaged inside blisters within the device. The single dose devices require the patient or caregiver to load a capsule of drug with each treatment, whereas the multiple dose devices typically contain a month’s supply of drug.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Humidity</strong> – High ambient humidity produces clumping of the powder, creating larger particles that are not as effectively aerosolized. DPI devices that use individually packaged capsules protect the powder from humidity and limit this effect. Patients should be instructed to exhale before inhaling through their DPI device. They should not exhale into the device, but rather exhale into the room. Also, any humidity that is introduced into the device will affect delivery of subsequent doses, especially for DPIs of the reservoir type [<a href="#rid2">2</a>]. For this reason, DPIs should be stored in a cool dry place. </p><p></p><p class="bulletIndent1">The effect of humidity and the need for a tight seal for breath actuation makes all DPIs <strong>inefficient</strong> for use in patients with a tracheostomy or endotracheal tube.</p><p></p><p>Examples of medications available in a DPI include short-acting beta-agonists (SABA)  (<a class="graphic graphic_table graphicRef72467" href="/z/d/graphic/72467.html" rel="external">table 2</a>), inhaled glucocorticoids (also called inhaled corticosteroids or ICS; eg, <a class="drug drug_general" data-topicid="9167" href="/z/d/drug information/9167.html" rel="external">budesonide</a>, <a class="drug drug_general" data-topicid="8951" href="/z/d/drug information/8951.html" rel="external">fluticasone</a>, <a class="drug drug_general" data-topicid="9663" href="/z/d/drug information/9663.html" rel="external">mometasone</a>)  (<a class="graphic graphic_table graphicRef78011" href="/z/d/graphic/78011.html" rel="external">table 3</a>), long-acting beta agonists (LABA; eg, <a class="drug drug_general" data-topicid="8946" href="/z/d/drug information/8946.html" rel="external">formoterol</a>, <a class="drug drug_general" data-topicid="16792" href="/z/d/drug information/16792.html" rel="external">indacaterol</a>, <a class="drug drug_general" data-topicid="9875" href="/z/d/drug information/9875.html" rel="external">salmeterol</a>)  (<a class="graphic graphic_table graphicRef122116" href="/z/d/graphic/122116.html" rel="external">table 7</a>), long-acting muscarinic antagonists (LAMA; eg, <a class="drug drug_general" data-topicid="86043" href="/z/d/drug information/86043.html" rel="external">aclidinium</a>, <a class="drug drug_general" data-topicid="8496" href="/z/d/drug information/8496.html" rel="external">glycopyrronium</a>, <a class="drug drug_general" data-topicid="10300" href="/z/d/drug information/10300.html" rel="external">tiotropium</a>, <a class="drug drug_general" data-topicid="95147" href="/z/d/drug information/95147.html" rel="external">umeclidinium</a>)  (<a class="graphic graphic_table graphicRef122118" href="/z/d/graphic/122118.html" rel="external">table 8</a>), and combinations such as LABA/ICS  (<a class="graphic graphic_table graphicRef68143" href="/z/d/graphic/68143.html" rel="external">table 4</a>), LABA/LAMA  (<a class="graphic graphic_table graphicRef116691" href="/z/d/graphic/116691.html" rel="external">table 5</a>), and LABA/LAMA/ICS  (<a class="graphic graphic_table graphicRef116691" href="/z/d/graphic/116691.html" rel="external">table 5</a>). The use of DPI devices is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/559.html" rel="external">"The use of inhaler devices in adults", section on 'DPI technique'</a> and  <a class="medical medical_review" href="/z/d/html/5738.html" rel="external">"The use of inhaler devices in children", section on 'Dry powder inhalers'</a>.) </p><p class="headingAnchor" id="H1503771169"><span class="h1">SOFT MIST INHALERS</span><span class="headingEndMark"> — </span>Soft mist inhalers (SMI; eg, Respimat) are aerosol delivery devices that have been formulated to aerosolize solutions through microelectronic dosimetric systems. When an SMI is manually primed (rotation of the lower half of the device compresses a spring), a measured amount of drug solution is drawn up into the dosing system. Pressing a button releases the spring, and the buildup of pressure forces the liquid through a nozzle structure within a uniblock that has two narrow outlet channels etched using microchip technology. The two jets of solution converge and the impact generates a soft mist aerosol for approximately 1.2 seconds. </p><p>The SMI aerosol has a high fine particle fraction, a low velocity, and more sustained duration than a pMDI [<a href="#rid38">38,39</a>]. The device has a dose indicator. Once the dose indicator reaches the red zone it alerts the patient that approximately 30 doses remain in the device. The device locks after all the doses have been actuated. </p><p>The SMI technology achieves a two-to-three fold higher pulmonary deposition than a pMDI [<a href="#rid40">40,41</a>]. Accordingly, the efficacy of a given dose of medication is higher when administered by SMI compared with conventional pMDIs [<a href="#rid42">42</a>].</p><p>Depending on geographic location, a variety of bronchodilators are available via SMI, including <a class="drug drug_general" data-topicid="8570" href="/z/d/drug information/8570.html" rel="external">ipratropium</a>, combination <a class="drug drug_general" data-topicid="8772" href="/z/d/drug information/8772.html" rel="external">ipratropium-albuterol</a>, <a class="drug drug_general" data-topicid="10300" href="/z/d/drug information/10300.html" rel="external">tiotropium</a>, combination <a class="drug drug_general" data-topicid="101635" href="/z/d/drug information/101635.html" rel="external">tiotropium-olodaterol</a>, and <a class="drug drug_general" data-topicid="96482" href="/z/d/drug information/96482.html" rel="external">olodaterol</a> alone. </p><p class="headingAnchor" id="H3"><span class="h1">NEBULIZERS</span><span class="headingEndMark"> — </span>The three basic types of nebulizer devices are jet (also known as pneumatic), ultrasonic, and mesh. Nebulizer performance is affected by both technical and patient-related factors  (<a class="graphic graphic_table graphicRef58515" href="/z/d/graphic/58515.html" rel="external">table 9</a>) [<a href="#rid43">43,44</a>]. </p><p class="headingAnchor" id="H339203"><span class="h2">Jet nebulizers</span><span class="headingEndMark"> — </span>The basic design of jet (pneumatic) nebulizers has changed little over the past 25 years  (<a class="graphic graphic_figure graphicRef57284" href="/z/d/graphic/57284.html" rel="external">figure 1</a>). Jet nebulizers are often considered interchangeable. However, differences in performance among nebulizers produced by various manufacturers have been reported [<a href="#rid45">45,46</a>]. Some nebulizers deliver the dose of medication in a shorter time, while others deliver a more accurate dose or have less drug wastage. These differences may not be important for delivery of inhaled bronchodilators, but may be significant for more expensive medication formulations where precise dosing is required. (See <a class="local">'Nebulizers for specific medications'</a> below and <a class="local">'Enhanced nebulizer designs'</a> below.)</p><p class="headingAnchor" id="H339577"><span class="h3">Mechanism</span><span class="headingEndMark"> — </span>The operation of a jet nebulizer requires an air compressor or a pressurized gas supply (eg, compressed air, oxygen), which acts as the driving force for liquid atomization. Compressed gas is delivered as a jet through a small orifice, generating a region of negative pressure above the medication reservoir. The solution to be aerosolized is first entrained, or pulled into the gas stream (Venturi effect), and then sheared into a liquid film. This film is unstable, and rapidly breaks into droplets due to surface tension forces.</p><p>A baffle placed in the aerosol stream allows formation of smaller droplets and recycling of larger droplets into the liquid reservoir. The aerosol of respirable particles is entrained into the inspiratory gas stream inhaled by the patient.</p><p class="headingAnchor" id="H10616854"><span class="h3">Technique</span><span class="headingEndMark"> — </span>The correct technique for use of a nebulizer is described in the table  (<a class="graphic graphic_table graphicRef71696" href="/z/d/graphic/71696.html" rel="external">table 10</a>) [<a href="#rid47">47</a>].</p><p class="headingAnchor" id="H20150710"><span class="h3">Factors affecting drug delivery</span><span class="headingEndMark"> — </span>A number of factors determine the efficiency of a nebulizer system, including the respirable dose, nebulization time, dead volume of the device, and the gas used to drive the nebulizer.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Respirable dose</strong> – The most important characteristic of nebulizer performance is the respirable dose delivered to the patient. The respirable dose is a function of the mass output of the nebulizer and the size of the droplets produced. Droplet size is usually reported as mass median aerodynamic diameter (MMAD), which is the median diameter around which the mass of the aerosol is equally divided. Droplet size should be 2 to 5 µm for airway deposition (eg, bronchodilator administration) and 1 to 2 µm or smaller for parenchymal deposition (eg, drugs intended for absorption into the bloodstream such as pulmonary vasodilators).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nebulization time</strong> – Nebulization time, the time required to deliver a dose of medication, is determined by the volume of drug to be delivered and the flow of the driving gas into the nebulizer. The larger the volume and the lower the flow, the longer the nebulization time. Nebulization time is an important determinant of patient compliance with completing a full dose in the outpatient setting. In addition, a reduction in nebulization time may decrease the need for clinical supervision in hospitalized or emergently-treated patients.</p><p></p><p class="bulletIndent1">During nebulization, the solution within the nebulizer becomes increasingly concentrated as water evaporates from the solution. Thus, on a per breath basis, more medication is delivered late in the course of a treatment. Patients should be encouraged to continue the treatment until there is no further pooling of medication in the bottom of the reservoir; nebulizer sputtering is a good sign that the treatment is complete. Continuing treatment after sputtering is of limited value.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dead volume</strong> – The volume of medication trapped inside the nebulizer, and therefore not available for inhalation, is referred to as the dead volume of the device. The dead volume is typically in the range of 1 to 3 mL. Increasing the amount of solution within the nebulizer (the fill volume) reduces the proportion of the dose lost as dead volume. Although nebulizer output increases with a greater fill volume, this also results in an increase in nebulization time. Considering both factors, an initial nebulizer fill volume of 4 to 5 mL is typically used [<a href="#rid46">46</a>]. The maximum fill volume of the nebulizer is manufacturer-determined; most do not exceed 5 mL, but some accept a volume as great as 10 mL. Unit dose ampules of bronchodilators (eg, <a class="drug drug_general" data-topicid="9396" href="/z/d/drug information/9396.html" rel="external">albuterol</a> and <a class="drug drug_general" data-topicid="8570" href="/z/d/drug information/8570.html" rel="external">ipratropium</a>) are typically 2.5 to 3 mL, which may not be ideal in terms of the proportion of dead volume to the total dose. However, the value of adding additional diluent to minimize the dead volume effect has not been studied.</p><p></p><p class="bulletIndent1">Unit dose ampules of antibiotics (eg, <a class="drug drug_general" data-topicid="10000" href="/z/d/drug information/10000.html" rel="external">tobramycin</a>) are 5 mL, which may be more suitable to minimize the dead volume effect. When combining drug solutions in the nebulizer to minimize the time required for treatment, it is important to avoid a drug volume that exceeds the labeled maximum volume of the nebulizer and to avoid any incompatibility issues of the drugs [<a href="#rid48">48</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Driving gas</strong> – Increasing the flow of the driving gas results in an increase in nebulized output and a reduction in particle size. A flow of 6 to 8 L/min is usually selected to optimize drug delivery [<a href="#rid46">46,49</a>]. When a compressor is used to power the nebulizer, instead of compressed air or oxygen from a wall device, the selected compressor should provide an adequate flow rate for drug aerosolization and delivery [<a href="#rid50">50-52</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Gas density</strong> – The density of the gas powering the nebulizer affects nebulizer performance. For example, the inhaled mass of <a class="drug drug_general" data-topicid="9396" href="/z/d/drug information/9396.html" rel="external">albuterol</a> is significantly reduced when a nebulizer is powered with a mixture of helium and oxygen (heliox). Accordingly, in the rare situation that the nebulizer is powered with heliox, the flow to the nebulizer is increased by 50 percent to 9 to 12 L/min [<a href="#rid53">53</a>]. Heliox may improve aerosol delivery to the lower respiratory tract, because the decrease in gas density results in creation of smaller particles; however, the clinical benefit of this approach is unclear [<a href="#rid54">54-59</a>]. (See  <a class="medical medical_review" href="/z/d/html/541.html" rel="external">"Physiology and clinical use of heliox"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Breathing pattern</strong> – The breathing pattern of the patient affects the amount of aerosol deposited in the lower respiratory tract. Airflow obstruction increases the need for inhaled bronchodilator therapy, but can decrease the effectiveness of that treatment. To improve aerosol penetration and deposition in the lungs, the patient should be encouraged to use a slow breathing pattern with a normal tidal volume and an occasional deep breath [<a href="#rid16">16</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nebulizer/compressor combination</strong> – When nebulizers are employed in the home, their performance is dependent on the choice of compressor that is used to drive the nebulizer. The flow rate of gas that drives the nebulizer is not the same as the flow rate from the compressor, which is usually higher [<a href="#rid60">60</a>]. The nebulizer/compressor combination employed must provide adequate flow rate and volume output from the nebulizer in an acceptable time period. Moreover, the aerosol generated should have an acceptable range of respirable particles [<a href="#rid61">61</a>]. Matching a nebulizer with a compressor is important for optimal performance and to ensure that the aerosol produced is therapeutic. (See <a class="local">'Nebulizers for specific medications'</a> below.)   </p><p></p><p class="headingAnchor" id="H10617078"><span class="h3">Continuous nebulization</span><span class="headingEndMark"> — </span>For patients with acute exacerbations of asthma, nebulized bronchodilators can be administered continuously, rather than intermittently at scheduled intervals [<a href="#rid1">1</a>]. (See <a class="local">'Asthma exacerbation'</a> below.)</p><p>One problem with continuous nebulization is the need for refilling the standard, small volume nebulizer every 10 to 15 minutes. Strategies to avoid frequent refilling of the nebulizer chamber for continuous nebulization include use of an infusion pump connected to the nebulizer and use of a large volume nebulizer [<a href="#rid43">43,62</a>]. The usual dose for continuous nebulization of <a class="drug drug_general" data-topicid="9396" href="/z/d/drug information/9396.html" rel="external">albuterol</a> is 10 to 15 mg/hour. Albuterol 0.5 percent (5 mg/mL) is available in a preservative-free 20 mL bottle [<a href="#rid63">63-65</a>]. This solution is diluted in respiratory <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a> to achieve a total volume of 4 to 5 mL in the nebulizer reservoir. Benzalkonium chloride, the preservative used in some multidose preparations of albuterol, may cause bronchoconstriction or delay resolution of bronchoconstriction in some patients [<a href="#rid64">64,66,67</a>].   </p><p>In general, drug delivery over time by continuous nebulization appears similar to that with frequent intermittent nebulization, although some large volume nebulizers may not provide as consistent a flow as a small volume nebulizer [<a href="#rid68">68-70</a>]. </p><p>Examples of nebulizers for continuous aerosolized bronchodilators include the HEART Nebulizer (Westmed) and the AirLife Misty Finity (Vyaire), Flo-Mist (Smiths Medical), and Hope (B&amp;B Medical Technologies) [<a href="#rid70">70</a>]. The driving gas flow for these large volume nebulizers should follow the manufacturers’ specifications. </p><p>Increasingly common is the use of a mesh nebulizer with an infusion pump for continuous aerosol treatment  (<a class="graphic graphic_figure graphicRef61793" href="/z/d/graphic/61793.html" rel="external">figure 2</a>). This can be used with a facemask or inline with a ventilator. Such a set-up is used not only for continuous aerosol bronchodilator delivery for acute asthma, but also for continuous <a class="drug drug_general" data-topicid="9411" href="/z/d/drug information/9411.html" rel="external">epoprostenol</a> inhalation for selective pulmonary vasodilation in critically ill patients. </p><p>Continuous aerosolized bronchodilators can be administered via high flow nasal cannula (HFNC), rather than the traditional facemask [<a href="#rid71">71,72</a>]. This approach has the advantage of being better tolerated by the patient and less likely to be interrupted due to removal of the face mask. When aerosols are delivered via a nebulizer and HFNC, the ratio of HFNC gas flow to patient’s inspiratory flow is critical; the optimal inhaled dose is achieved with the HFNC gas flow set at about 50 percent of patient’s inspiratory flow. (See <a class="local">'Patients using high flow nasal cannula'</a> below.) </p><p class="headingAnchor" id="H339423"><span class="h2">Mesh nebulizers</span><span class="headingEndMark"> — </span>Several manufacturers have developed aerosol devices that use a mesh or plate with multiple apertures to produce a liquid aerosol  (<a class="graphic graphic_figure graphicRef69736" href="/z/d/graphic/69736.html" rel="external">figure 3</a>) [<a href="#rid73">73</a>]. The solution or suspension of medication is forced through the mesh to produce an aerosol, without need for an internal baffling system or compressed air source [<a href="#rid74">74</a>]. A common feature of these devices is their ability to generate aerosols with a high fine-particle fraction, which results in more efficient drug delivery compared to conventional nebulizers.</p><p>Examples of mesh nebulizers include the eFlow (Pari), Aeroneb Solo and Aeroneb Go (Aerogen), MicroAIR/NE-U22 (OMRON), InnoSpire Go (Philips) and the I-neb (Respironics)  (<a class="graphic graphic_picture graphicRef87397" href="/z/d/graphic/87397.html" rel="external">picture 4</a>). These nebulizers are portable, battery-operated, and have minimal residual medication volume [<a href="#rid73">73</a>]. Another advantage to mesh technology is the ability to deliver expensive formulations with precise dosing and minimal wastage [<a href="#rid75">75</a>] such as the Altera Nebulizer System for administration of <a class="drug drug_general" data-topicid="9047" href="/z/d/drug information/9047.html" rel="external">aztreonam</a>, and the Lamira for administration of <a class="drug drug_general" data-topicid="8536" href="/z/d/drug information/8536.html" rel="external">amikacin</a>, each of which utilizes the eFlow technology. Some mesh nebulizers can be used with a holding chamber (eg, Aerogen Ultra).</p><p>The I-neb nebulizer uses mesh technology combined with Adaptive Aerosol Delivery (ADD). ADD monitors the patient's breathing pattern and injects a programable dose of the aerosol at the beginning of inhalation [<a href="#rid76">76</a>]. This improves the likelihood of the aerosol penetrating deep into the respiratory tract. This nebulizer is used specifically for the administration of <a class="drug drug_general" data-topicid="8895" href="/z/d/drug information/8895.html" rel="external">iloprost</a> (Ventavis) inhalation solution for the treatment of pulmonary arterial hypertension  (<a class="graphic graphic_figure graphicRef79862" href="/z/d/graphic/79862.html" rel="external">figure 4</a>). (See  <a class="medical medical_review" href="/z/d/html/8250.html" rel="external">"Treatment of pulmonary arterial hypertension (group 1) in adults: Pulmonary hypertension-specific therapy"</a>.)</p><p>In general, mesh nebulizers are more light-weight and portable than jet nebulizers. Mesh nebulizers usually deliver the medication dose more quickly than jet nebulizers and could reduce the duration of each nebulizer treatment. However, the speed of medication delivery is influenced by the position of the nebulizer. Under laboratory conditions, the Omron vibrating mesh nebulizer has a comparable drug delivery to a conventional jet nebulizer only when the Omron is in a vertical position [<a href="#rid77">77</a>]. The time to deliver the same dose is three times longer when the Omron is in the horizontal position, rather than vertical or slightly tilted. </p><p>Blockage of the minute apertures with drug particles, especially when suspensions are aerosolized, can impair performance. Thus, manufacturer’s recommendations for cleaning the device should be followed meticulously. Cleaning is required after each treatment, and more extensive disinfection or sterilization needs to be performed on a regular basis. One study reported that the Aerogen Solo mesh nebulizer was often randomly interrupted with a wide range of retained volumes, so the chamber should be checked to ensure that the full dose has been delivered [<a href="#rid78">78</a>].</p><p class="headingAnchor" id="H339430"><span class="h2">Ultrasonic nebulizers</span><span class="headingEndMark"> — </span>Ultrasonic nebulizers consist of a power unit and transducer, with or without an electric fan [<a href="#rid43">43,79</a>]. The power unit converts electrical energy to high-frequency ultrasonic waves. A piezoelectric element in the transducer vibrates at the same frequency as the applied wave. Ultrasonic waves are transmitted to the surface of the solution to create an aerosol. The droplets produced by these devices have a slightly higher MMAD than droplets from a jet nebulizer [<a href="#rid80">80</a>]. A fan is used to deliver the aerosol to the patient, or the aerosol is evacuated from the nebulization chamber by the inspiratory flow of the patient.</p><p>Small volume ultrasonic nebulizers (eg, Beetle Neb, Lumiscope, Minibreeze) are commercially available for delivery of bronchodilators. Advantages of ultrasonic nebulization are quieter medication delivery and shorter treatment time than the jet nebulizers. Reported problems include poor battery life and overheating. A potential issue with the use of ultrasonic nebulizers is drug inactivation by increased temperature of the solution during ultrasonic nebulization. Drug inactivation has not been shown to occur with the medications in solution that are commonly delivered using this system (eg, bronchodilators). Additionally, ultrasonic nebulizers create aerosol droplets from the surface of the liquid. In suspensions, such as <a class="drug drug_general" data-topicid="9167" href="/z/d/drug information/9167.html" rel="external">budesonide</a>, the drug particles tend to settle and ultrasonic nebulizers are inefficient for aerosolization of suspensions.</p><p>The Optineb is an ultrasonic nebulizer used to deliver <a class="drug drug_general" data-topicid="10207" href="/z/d/drug information/10207.html" rel="external">treprostinil</a> inhalation solution for the treatment of pulmonary hypertension. The device is specific for the delivery of treprostinil and prompts the patient to use correct inhalation technique.</p><p class="headingAnchor" id="H9"><span class="h2">Enhanced nebulizer designs</span><span class="headingEndMark"> — </span>Newer technologies for nebulizer design address issues of medication conservation, speed of delivery of medication, portability, battery power, and administration of specialized medications. With the traditional nebulizer design, an aerosol is generated throughout the patient's respiratory cycle. This results in considerable waste of aerosol during exhalation. Newer designs reduce aerosol waste during the exhalation phase  (<a class="graphic graphic_picture graphicRef56942" href="/z/d/graphic/56942.html" rel="external">picture 5</a>).</p><p class="bulletIndent1"><span class="glyph">●</span>Breath-enhanced nebulizers, such as the Pari LC, are designed to allow release of more aerosolized medication during inhalation than exhalation. With this design, exhaled gas is routed out the expiratory valve in the mouthpiece and aerosol is contained in the nebulizer chamber during the expiratory phase.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The Circulaire nebulizers reduce waste from a constant-output nebulizer by attachment of a storage bag with a one-way valve in the mouthpiece connector. During the expiratory phase, aerosol generated by the nebulizer is collected in the bag and delivered to the patient on the subsequent inhalation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The AeroEclipse nebulizer has a breath-actuated valve that triggers aerosol generation only during inhalation, eliminating the need for a storage bag or reservoir [<a href="#rid81">81</a>]. A randomized controlled trial has reported benefit for the use of this nebulizer compared to a jet nebulizer in a pediatric emergency department setting [<a href="#rid82">82</a>].</p><p></p><p class="headingAnchor" id="H339955"><span class="h2">Mouthpieces and facemasks</span><span class="headingEndMark"> — </span>Inhaled aerosols from nebulizers can be administered using a mouthpiece or a facemask, although the mouthpiece interface is generally preferred.</p><p>Bronchodilator response appears similar with either interface, and some have argued that the selection of patient interface should be based upon patient preference. Significant facial and eye deposition of aerosol can occur when a face mask is used, especially in young children [<a href="#rid83">83</a>]. Eye deposition is of particular concern when aerosolized anticholinergic agents (eg, <a class="drug drug_general" data-topicid="8570" href="/z/d/drug information/8570.html" rel="external">ipratropium</a>) are administered, as this can result in blurring of vision, pupil dilation, and worsening of narrow angle glaucoma. When a facemask is used, it is important to instruct the patient to inhale through the mouth to minimize nasopharyngeal deposition of medication.</p><p class="headingAnchor" id="H119742109"><span class="h2">Infection control</span><span class="headingEndMark"> — </span>Nebulization significantly increases aerosol concentration in the patient’s vicinity (fugitive aerosols), particularly within one meter (approximately three feet) of the patient, and can provoke coughing or sneezing [<a href="#rid84">84,85</a>], raising the possibility that use of aerosolized therapies might disperse infectious bio-aerosols and cross-infect health care workers [<a href="#rid86">86-88</a>]. </p><p>During a nebulizer treatment, the exhaled air from the patient passes over the reservoir in standard jet nebulizers potentially contaminating the reservoir with respiratory secretions. In modeling studies, jet nebulization led to 0.8 meter dispersion of the exhaled aerosol with more extensive dispersion in models with stiffer lungs mimicking severe lung injury [<a href="#rid87">87</a>]. Coughs provoked during nebulizer or inhaler therapy can disperse large respiratory droplets over approximately two meters, while smaller droplet nuclei can travel further. It is uncertain whether aerosols generated from nebulizer administration are infectious [<a href="#rid89">89,90</a>]. </p><p>For patients infected with respiratory viruses, interventions that may decrease the risk of virus spread during administration of inhaled medications include the following [<a href="#rid91">91,92</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Use a dry powder inhaler (DPI), soft mist inhaler (SMI), or pressurized metered dose inhaler (pMDI) to deliver respiratory medications instead of a nebulizer (when possible). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Use a mouthpiece rather than a mask for inhalation of the nebulized medication and place a filter on the exhalation port of the nebulizer and instruct the patient to seal their lips tightly around the mouthpiece during inhalation and exhalation. Commercially available systems are available to filter or scavenge fugitive aerosols (SafetyNeb, Exhalo Shield, Tavish filter mask, face tent attached to vacuum); whether or not such systems are necessary is yet to be determined.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Consider use of a breath synchronized nebulizer that only generates an aerosol during inhalation to minimize the release of medical aerosols [<a href="#rid87">87</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Advise health care workers to stay two meters away from the infected patient during procedures that provoke cough or sneeze or generate an aerosol and to wear N95 or other respirators (eg, a powered air-purifying respirator [PAPR]), eye protection (eg, goggles or a disposable face shield that covers the front and sides of the face), gloves, and a gown [<a href="#rid93">93-95</a>]. Closing the door to the room during the treatment and a negative pressure room are additional considerations.</p><p></p><p>Additional information about infection control for aerosol-generating procedures in the setting of COVID-19 is provided separately. (See  <a class="medical medical_review" href="/z/d/html/127501.html" rel="external">"COVID-19: Infection prevention for persons with SARS-CoV-2 infection"</a> and  <a class="medical medical_review" href="/z/d/html/127501.html" rel="external">"COVID-19: Infection prevention for persons with SARS-CoV-2 infection", section on 'Aerosol-generating procedures/treatments'</a>.)</p><p class="headingAnchor" id="H339088"><span class="h1">AEROSOL DELIVERY IN SPECIAL SITUATIONS</span></p><p class="headingAnchor" id="H3231244268"><span class="h2">Mixing nebulized medications</span><span class="headingEndMark"> — </span>Some patients need more than one nebulized medication, such as one or more bronchodilators or a bronchodilator plus glucocorticoid or hypertonic <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a>. Certain preparations are compatible and can be mixed into a single nebulizer treatment, thus improving patient convenience. However, caution is necessary as certain mixtures are incompatible due to changes in particle size or other characteristics. As an example, hypertonic sodium chloride is compatible with <a class="drug drug_general" data-topicid="9167" href="/z/d/drug information/9167.html" rel="external">budesonide</a>, but not with <a class="drug drug_general" data-topicid="9396" href="/z/d/drug information/9396.html" rel="external">albuterol</a>, <a class="drug drug_general" data-topicid="8946" href="/z/d/drug information/8946.html" rel="external">formoterol</a>, <a class="drug drug_general" data-topicid="8570" href="/z/d/drug information/8570.html" rel="external">ipratropium</a>, or <a class="drug drug_general" data-topicid="8951" href="/z/d/drug information/8951.html" rel="external">fluticasone</a>. A listing of compatible and incompatible solutions is provided in the table  (<a class="graphic graphic_table graphicRef122909" href="/z/d/graphic/122909.html" rel="external">table 11</a>).</p><p>When mixing nebulized medications, freshly opened, single use formulations should be used.</p><p class="headingAnchor" id="H24790161"><span class="h2">Nebulizers for specific medications</span><span class="headingEndMark"> — </span>Drug formulation can affect nebulizer performance, and some drug preparations are only approved for delivery with specific nebulizers  (<a class="graphic graphic_table graphicRef83376" href="/z/d/graphic/83376.html" rel="external">table 12</a>) [<a href="#rid96">96-99</a>]. Examples of medications that should be delivered <strong>only</strong> by an approved nebulizer include <a class="drug drug_general" data-topicid="9167" href="/z/d/drug information/9167.html" rel="external">budesonide</a> suspension, <a class="drug drug_general" data-topicid="8895" href="/z/d/drug information/8895.html" rel="external">iloprost</a>, <a class="drug drug_general" data-topicid="9752" href="/z/d/drug information/9752.html" rel="external">pentamidine</a>, <a class="drug drug_general" data-topicid="9860" href="/z/d/drug information/9860.html" rel="external">ribavirin</a>, DNase I, <a class="drug drug_general" data-topicid="10000" href="/z/d/drug information/10000.html" rel="external">tobramycin</a>, <a class="drug drug_general" data-topicid="9047" href="/z/d/drug information/9047.html" rel="external">aztreonam</a>, <a class="drug drug_general" data-topicid="10207" href="/z/d/drug information/10207.html" rel="external">treprostinil</a>, <a class="drug drug_general" data-topicid="119622" href="/z/d/drug information/119622.html" rel="external">revefenacin</a>, and liposomal <a class="drug drug_general" data-topicid="8536" href="/z/d/drug information/8536.html" rel="external">amikacin</a>, as described below.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Budesonide</strong> - <a class="drug drug_general" data-topicid="9167" href="/z/d/drug information/9167.html" rel="external">Budesonide</a> is prepared as a suspension for nebulization. It can be administered via jet or mesh nebulizers, but not by an ultrasonic nebulizer. (See <a class="local">'Ultrasonic nebulizers'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Iloprost</strong> – <a class="drug drug_general" data-topicid="8895" href="/z/d/drug information/8895.html" rel="external">Iloprost</a> requires use of a nebulizer with an Adaptive Aerosol Delivery (AAD) system that controls the dosage of drug by use of a specialized disc and metering chambers. Two types of nebulizer are acceptable, the vibrating mesh nebulizer I-neb AAD (Respironics) and the jet nebulizer Prodose AAD (Respironics) [<a href="#rid76">76</a>]. The AAD metering chambers can deliver a pre-set volume ranging from 0.25 to 1.4 mL with a residual of about 0.1 mL. The drug is only delivered during inspiration and requires that the patient be conscious and breathing spontaneously [<a href="#rid100">100,101</a>]. </p><p></p><p class="bulletIndent1">The I-neb AAD delivers aerosol via two modes of inspiration: the tidal breathing mode, in which the aerosol is delivered during the first 50 percent of the patient’s inspiration or a new target inhalation mode (TIM) which guides the patient to a slow and deep inspiration. Typical inspiratory flows are reduced to approximately 20 L/min by introduction of a high-resistance mouthpiece. The device provides feedback (by a vibration signal) to gradually lengthen the duration of inspiration with each breath, until the inhalation time matches a target inhalation time. At this time, aerosol generation occurs over &gt;70 percent of the inspiration. The device remembers this breathing pattern and gives a vibratory feedback at the same point in each successive breath and for all future treatments. The slow and deep breathing combined with AAD greatly enhances drug delivery and pulmonary deposition compared to tidal breathing [<a href="#rid100">100,101</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pentamidine</strong> – Specially constructed small-volume jet nebulizers, such as the Respirgard II, are used when it is necessary to prevent contamination of the ambient environment with the aerosolized drug (eg, <a class="drug drug_general" data-topicid="9752" href="/z/d/drug information/9752.html" rel="external">pentamidine</a>) [<a href="#rid43">43</a>]. The Respirgard II is fitted with one-way valves and filters to minimize gross contamination of the environment. (See  <a class="medical medical_review" href="/z/d/html/3709.html" rel="external">"Treatment and prevention of Pneumocystis infection in patients with HIV", section on 'Patients with a sulfa allergy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ribavirin</strong> – A specialized jet nebulizer is used to allow the safe delivery of aerosolized <a class="drug drug_general" data-topicid="9860" href="/z/d/drug information/9860.html" rel="external">ribavirin</a>, which is potentially teratogenic. The Valeant Small-Particle Aerosol Generator (SPAG-2) is designed specifically to aerosolize ribavirin. It consists of a nebulizer and drying chamber that reduces the MMAD to about 1.3 µm, which optimizes drug delivery to distal airspaces. The SPAG-2 is used with a scavenging system to minimize contamination of the ambient environment. (See  <a class="medical medical_review" href="/z/d/html/6001.html" rel="external">"Respiratory syncytial virus infection: Treatment in infants and children", section on 'Ribavirin'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>DNase I (Dornase alfa)</strong> – Inhaled DNase I (Dornase alfa) is administered to patients with cystic fibrosis using the Pulmo-Aide, Pari-Proneb, Mobilaire, Porta-Neb, or Pari Baby jet nebulizer systems. (See  <a class="medical medical_review" href="/z/d/html/6372.html" rel="external">"Cystic fibrosis: Overview of the treatment of lung disease", section on 'Inhaled airway clearance agents'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tobramycin</strong> – Inhaled <a class="drug drug_general" data-topicid="10000" href="/z/d/drug information/10000.html" rel="external">tobramycin</a> is administered over 20 minutes using a handheld jet nebulizer (PARI-LC PLUS). It cannot be combined with other inhaled medications. (See  <a class="medical medical_review" href="/z/d/html/6371.html" rel="external">"Cystic fibrosis: Antibiotic therapy for chronic pulmonary infection", section on 'Inhaled tobramycin'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Aztreonam</strong> – Inhaled <a class="drug drug_general" data-topicid="9047" href="/z/d/drug information/9047.html" rel="external">aztreonam</a> is administered using the Altera Nebulizer System, which uses mesh nebulizer technology. (See <a class="local">'Mesh nebulizers'</a> above and  <a class="medical medical_review" href="/z/d/html/6371.html" rel="external">"Cystic fibrosis: Antibiotic therapy for chronic pulmonary infection", section on 'Inhaled aztreonam lysine'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treprostinil</strong> – Inhaled <a class="drug drug_general" data-topicid="10207" href="/z/d/drug information/10207.html" rel="external">treprostinil</a> is used to treat pulmonary arterial hypertension (PAH; WHO Group I) in patients with NYHA class III symptoms. It is delivered with the Optineb ultrasonic nebulizer. (See  <a class="medical medical_review" href="/z/d/html/8250.html" rel="external">"Treatment of pulmonary arterial hypertension (group 1) in adults: Pulmonary hypertension-specific therapy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Revefenacin</strong> – (Yupelri) inhalation solution is the only once-daily, nebulized bronchodilator for maintenance treatment of COPD [<a href="#rid102">102,103</a>]. <a class="drug drug_general" data-topicid="119622" href="/z/d/drug information/119622.html" rel="external">Revefenacin</a> is a LAMA and is nebulized with a standard jet nebulizer connected to a compressor. (See  <a class="medical medical_review" href="/z/d/html/1450.html" rel="external">"Role of muscarinic antagonist therapy in COPD", section on 'Revefenacin'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Amikacin</strong> – <a class="drug drug_general" data-topicid="8536" href="/z/d/drug information/8536.html" rel="external">Amikacin</a> (Arikayce) liposome inhalation suspension is delivered once daily with the Lamira mesh nebulizer system. During nebulization, approximately 70 percent of the amikacin dose remains encapsulated within liposomes while approximately 30 percent of the dose is released as free amikacin. Nebulized amikacin is indicated for patients who remain culture positive after six months of multi-drug treatment for <em>Mycobacterium avium complex</em> (MAC) [<a href="#rid104">104,105</a>]. (See  <a class="medical medical_review" href="/z/d/html/5341.html" rel="external">"Treatment of <i>Mycobacterium avium </i>complex pulmonary infection in adults", section on 'Efficacy of alternative agents'</a>.)</p><p></p><p class="headingAnchor" id="H340028"><span class="h2">Asthma exacerbation</span><span class="headingEndMark"> — </span>Two issues that arise when choosing an aerosol delivery system for bronchodilator medication during exacerbations of asthma are whether to use an MDI or a nebulizer and whether to use continuous or intermittent nebulization for hospital-based treatment. These choices are typically based on the severity of the exacerbation and also clinician and patient preference  (<a class="graphic graphic_algorithm graphicRef111835" href="/z/d/graphic/111835.html" rel="external">algorithm 1</a>). (See  <a class="medical medical_review" href="/z/d/html/119093.html" rel="external">"Acute exacerbations of asthma in adults: Emergency department and inpatient management"</a>.)</p><p>For patients who have an asthma exacerbation that is mild to moderate in severity (eg, mild to no dyspnea at rest and peak expiratory flow ≥40 percent of predicted), administration of the beta 2-agonist <a class="drug drug_general" data-topicid="9396" href="/z/d/drug information/9396.html" rel="external">albuterol</a> via a pMDI (2 to 6 puffs for treatment at home, 4 to 8 puffs for emergency room or hospital treatment) combined with a spacer or chamber device (eg, Aerochamber, Optichamber Diamond, Vortex) results in comparable improvements in lung function compared to nebulizer delivery, although the actual dose delivered by a pMDI is much lower  (<a class="graphic graphic_table graphicRef72467" href="/z/d/graphic/72467.html" rel="external">table 2</a>). Similar results with pMDIs have been reported in patients with severe exacerbations, but only a small number of such patients have been studied. Generally, nebulizer treatments (every 20 minutes or continuous) are preferred for more severe asthma exacerbations. (See  <a class="medical medical_review" href="/z/d/html/119093.html" rel="external">"Acute exacerbations of asthma in adults: Emergency department and inpatient management", section on 'Nebulizer versus MDI'</a>.)</p><p>For patients with severe asthma exacerbations (eg, dyspnea at rest, accessory muscle use, retractions, forced expiratory volume in one second or peak expiratory flow &lt;40 percent predicted), beta agonists are often administered continuously (eg, <a class="drug drug_general" data-topicid="9396" href="/z/d/drug information/9396.html" rel="external">albuterol</a> 5 to 15 mg/hour) rather than intermittently [<a href="#rid16">16,106,107</a>]. This method of bronchodilator administration is equally effective compared to frequent intermittent nebulization [<a href="#rid8">8,108</a>]. </p><p>Several studies have established the safety of continuous nebulization, even when high doses (eg, 20 mg/hour of <a class="drug drug_general" data-topicid="9396" href="/z/d/drug information/9396.html" rel="external">albuterol</a>) are used [<a href="#rid43">43,106,109</a>]. However, continuous nebulization of albuterol (10 mg/hour) in healthy adults has been associated with a decrease in serum potassium of 0.5 mmol/L (95% CI: -0.72 to -0.28 mmol/L), which could be clinically important in patients with a low potassium level prior to therapy [<a href="#rid110">110</a>].</p><p>Continuous nebulization may be most beneficial in patients with the most severe pulmonary dysfunction [<a href="#rid106">106</a>]. The specialized delivery systems adapted for continuous nebulization are described above. (See <a class="local">'Continuous nebulization'</a> above.)</p><p class="headingAnchor" id="H18"><span class="h2">Patients with tracheostomy</span><span class="headingEndMark"> — </span>Techniques have been developed for the delivery of aerosol medication by nebulizer or pMDI to patients with a tracheostomy tube who are not ventilator dependent  (<a class="graphic graphic_picture graphicRef70613" href="/z/d/graphic/70613.html" rel="external">picture 6</a>) [<a href="#rid111">111</a>]. Two systems are available for delivery of nebulized medication: either a mask can be placed over the tracheostomy opening or the nebulizer chamber can be attached to the tracheostomy tube using a T-piece made of ventilator tubing and a connector. The T-piece approach is preferred because more aerosol medication is directed into the tracheostomy tube.</p><p>For delivery of a pMDI aerosol, the canister is removed from its usual plastic actuator and inserted into an actuator/spacer that is attached by T-shaped connector to the tracheostomy tube. This actuator/spacer is the same as that used for patients on mechanical ventilation  (<a class="graphic graphic_picture graphicRef53295" href="/z/d/graphic/53295.html" rel="external">picture 7</a>). The caregiver actuates the pMDI into the spacer and the patient inhales the aerosol through the tracheostomy tube.</p><p>Adaptors have not been developed for effective administration of medication from DPIs into tracheostomy tubes [<a href="#rid112">112</a>].</p><p class="headingAnchor" id="H19"><span class="h2">Mechanically ventilated patients</span><span class="headingEndMark"> — </span>A number of factors affect aerosol delivery during mechanical ventilation  (<a class="graphic graphic_table graphicRef64944" href="/z/d/graphic/64944.html" rel="external">table 13</a>) [<a href="#rid113">113-124</a>]. One major factor is that humidification of inhaled gas decreases aerosol deposition by approximately 40 percent due to increased particle drug deposition in the ventilator circuit. For this reason, increased dosage of medication is often required to achieve a therapeutic effect in mechanically ventilated patients.</p><p>Inhaled medications can be delivered to patients receiving mechanical ventilation using either a pMDI or a nebulizer [<a href="#rid116">116,117</a>]. A DPI is inefficient for delivery of a dry powder during mechanical ventilation because ventilator circuit humidification impairs aerosol formation.</p><p class="headingAnchor" id="H20"><span class="h3">Metered dose inhaler</span><span class="headingEndMark"> — </span>A special actuator is needed to adapt the pMDI into the ventilator circuit  (<a class="graphic graphic_picture graphicRef53295" href="/z/d/graphic/53295.html" rel="external">picture 7</a>) [<a href="#rid125">125,126</a>]. The size, shape, and design of these actuators have a major impact on drug delivery to the patient. A pMDI with a chamber results in a four- to six-fold greater delivery of aerosol than MDI actuation into a connector attached directly to the endotracheal tube, or into an in-line device that lacks a chamber [<a href="#rid116">116</a>]. When using a pMDI during mechanical ventilation, it is important to synchronize actuation with inspiratory airflow to optimize drug delivery. Properly used, a pMDI may deliver a more consistent dose than a nebulizer [<a href="#rid127">127</a>].</p><p>The following technique has been proposed for using pMDIs in mechanically ventilated adult patients [<a href="#rid128">128</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Shake the pMDI vigorously</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Place canister in the actuator of a cylindrical spacer situated in the inspiratory limb of ventilator circuit  (<a class="graphic graphic_picture graphicRef53295" href="/z/d/graphic/53295.html" rel="external">picture 7</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Actuate the pMDI once only with the onset of inspiration by the ventilator</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Repeat actuations after 15 seconds until the total dose is delivered</p><p></p><p>Helium-oxygen mixtures affect aerosol deposition, and in vitro modeling has reported a 50 percent increase in deposition of <a class="drug drug_general" data-topicid="9396" href="/z/d/drug information/9396.html" rel="external">albuterol</a> from a pMDI during mechanical ventilation when heliox was used as the driving gas [<a href="#rid129">129</a>]. However, heliox can interfere with the functioning of flow sensors and oxygen levels when delivered through some ventilators, and care must be taken if this approach is employed with a ventilator that is not approved for heliox administration [<a href="#rid130">130-132</a>]. (See  <a class="medical medical_review" href="/z/d/html/541.html" rel="external">"Physiology and clinical use of heliox", section on 'Instrument recalibration'</a>.)</p><p>The use of a heat and moisture exchanger (HME) in the ventilator circuit can filter out the aerosol when a pMDI (or nebulizer) is used. Commercially available devices can be used to bypass the HME when a pMDI is used  (<a class="graphic graphic_picture graphicRef50376" href="/z/d/graphic/50376.html" rel="external">picture 8</a> and <a class="graphic graphic_picture graphicRef80294" href="/z/d/graphic/80294.html" rel="external">picture 9</a>). Alternatively, the HME must be removed from the circuit when the aerosol is delivered [<a href="#rid133">133</a>].</p><p class="headingAnchor" id="H21"><span class="h3">Nebulizer</span><span class="headingEndMark"> — </span>The optimal methods for delivery of nebulized medication to mechanically ventilated patients are not well-established. Delivery of a large tidal volume, use of an end-inspiratory pause, and use of a slow inspiratory flow affect aerosol delivery by jet nebulizer but <strong>not</strong> by a pMDI [<a href="#rid113">113</a>]. Nebulizer performance can be optimized by placing the nebulizer 30 cm from the endotracheal tube, rather than at the Y-piece, because the inspiratory ventilator tubing acts as a spacer. In a simulation model, delivery of <a class="drug drug_general" data-topicid="9396" href="/z/d/drug information/9396.html" rel="external">albuterol</a> via mesh nebulizer was two to four times greater than with a jet nebulizer, and placement of the mesh nebulizer in the ventilator tubing on the ventilator side of the humidifier, rather than closer to the patient, increased drug delivery [<a href="#rid118">118</a>]. </p><p>Operating the nebulizer only during inspiration is more efficient for aerosol delivery compared with continuous aerosol generation throughout the respiratory cycle. When a breath-actuated nebulizer is used, the delivered dose increases by more than five-fold. In addition, when the humidifier is bypassed the delivered dose increases by a factor of nearly four [<a href="#rid114">114</a>].</p><p>Disadvantages of jet nebulizer use during mechanical ventilation include circuit contamination due to opening the ventilator tubing circuit, decreased ability of the patient to trigger the ventilator, and the associated increases in tidal volume and airway pressure due to nebulizer flow. Valved T-piece devices are commercially available and commonly used to allow the nebulizer to be inserted within the ventilator circuit without disconnecting the patient from the ventilator, thus avoiding interruption of mechanical ventilation for nebulizer insertion and removal  (<a class="graphic graphic_picture graphicRef71363" href="/z/d/graphic/71363.html" rel="external">picture 10</a>). (See  <a class="medical medical_review" href="/z/d/html/1656.html" rel="external">"The ventilator circuit"</a>.) A filter in the expiratory limb during the nebulizer treatment protects the expiratory valve and flow/pressure monitors.</p><p>The mesh nebulizer can be used effectively during mechanical ventilation and is placed between the ventilator outlet and the heated humidifier [<a href="#rid118">118,134</a>]. Unlike the jet nebulizer, the mesh nebulizer remains in the ventilator circuit and does not interfere with ventilator function (eg, no additional gas flow, no effect on triggering). (See <a class="local">'Mesh nebulizers'</a> above.)</p><p class="headingAnchor" id="H22"><span class="h3">Choice of device</span><span class="headingEndMark"> — </span>Although the jet nebulizer is less efficient than the pMDI during mechanical ventilation, the nebulizer can deliver a greater cumulative dose to the lower respiratory tract [<a href="#rid135">135</a>]. Thus, nebulizers and pMDIs produce similar therapeutic effects in mechanically ventilated patients [<a href="#rid136">136</a>]. The use of a pMDI for routine bronchodilator therapy in ventilator-supported patients has been preferred because of the problems associated with the use of nebulizers, including contamination and triggering difficulty, as well as increased pressure and volume delivery. However, use of a mesh nebulizer avoids several of the problems of the jet nebulizer and performs comparably to pMDIs. Compared with the pMDI, the mesh nebulizer is a convenient and efficient delivery method in mechanically ventilated patients [<a href="#rid137">137</a>]. </p><p>Aerosol delivery by pMDI is easy to administer, involves less personnel time than a nebulizer, provides a reliable dose of the drug, and is free from the risk of bacterial contamination. When a pMDI is used with an in-line spacer, the ventilator circuit does not need to be disconnected with each treatment; this may reduce the risk of ventilator-associated pneumonia. This also prevents the loss of positive end-expiratory pressure (PEEP) in patients with acute lung injury (ALI) and acute respiratory distress syndrome (ARDS). (See  <a class="medical medical_review" href="/z/d/html/1656.html" rel="external">"The ventilator circuit"</a> and  <a class="medical medical_review" href="/z/d/html/1653.html" rel="external">"Acute respiratory distress syndrome: Ventilator management strategies for adults"</a>.)</p><p class="headingAnchor" id="H2275128272"><span class="h2">Patients receiving noninvasive ventilation</span><span class="headingEndMark"> — </span>Aerosol therapy can also be administered during noninvasive positive pressure ventilation (NIV), using devices adapted for inline administration  (<a class="graphic graphic_picture graphicRef79663" href="/z/d/graphic/79663.html" rel="external">picture 11</a>) [<a href="#rid138">138-142</a>]. Effective delivery of <a class="drug drug_general" data-topicid="9396" href="/z/d/drug information/9396.html" rel="external">albuterol</a> by MDI during NIV using a specialized spacer has been reported in patients with exacerbations of chronic obstructive pulmonary disease (COPD) [<a href="#rid143">143</a>]. When delivering aerosol therapy during NIV, the aerosol generator should be placed between the leak port and the interface. (See  <a class="medical medical_review" href="/z/d/html/528.html" rel="external">"Acute exacerbations of asthma in adults: Home and office management"</a> and  <a class="medical medical_review" href="/z/d/html/1636.html" rel="external">"Noninvasive ventilation in adults with acute respiratory failure: Benefits and contraindications"</a>.) </p><p class="headingAnchor" id="H3995279508"><span class="h2">Patients using high flow nasal cannula</span><span class="headingEndMark"> — </span>The high flow nasal cannula is increasingly used for hypoxemic respiratory failure and can also be used for aerosol delivery in the intensive care unit (ICU) [<a href="#rid144">144,145</a>]. The results of <em>in vitro</em> studies suggest that aerosols can be delivered by HFNC, and there is anecdotal experience suggesting benefit [<a href="#rid71">71</a>]. When aerosols are delivered via a nebulizer and HFNC, the ratio of HFNC gas flow to patient’s inspiratory flow is critical; optimal inhaled dose is achieved with the HFNC gas flow set at about 50 percent of patient’s inspiratory flow [<a href="#rid146">146</a>]. At high flows, the amount of aerosol delivery is likely to be very low [<a href="#rid71">71,72</a>]. In one study, pulmonary drug delivery through the high-flow nasal cannula was about 1 to 4 percent of the amount placed in the nebulizer, with a higher efficiency for a mesh nebulizer than a jet nebulizer [<a href="#rid17">17</a>]. However, in a separate study of 26 subjects with COPD, the physiologic response to inhaled bronchodilator was similar for mouthpiece and nasal cannula at a flow of 35 L/minute [<a href="#rid147">147</a>]. In 42 stable asthma and COPD patients with known positive responses to 400 mcg <a class="drug drug_general" data-topicid="9396" href="/z/d/drug information/9396.html" rel="external">albuterol</a> via pMDI and spacer, the bronchodilator response to albuterol 1.5 mg via a vibrating mesh nebulizer and HFNC with gas flow of 15 to 20 L/min was similar to that achieved with albuterol 400 mcg by pMDI with spacer [<a href="#rid146">146,148</a>]. The lower deposition with high flow nasal cannula might also be overcome by increasing the dose [<a href="#rid71">71</a>]. A pMDI, SMI, or DPI device cannot be used with high flow nasal cannula. (See  <a class="medical medical_review" href="/z/d/html/6394.html" rel="external">"Continuous oxygen delivery systems for the acute care of infants, children, and adults", section on 'Nasal cannula'</a>.)</p><p class="headingAnchor" id="H20210883"><span class="h2">Home use</span><span class="headingEndMark"> — </span>Prescription of a nebulizer for home use is usually not necessary for patients with asthma or COPD due to the efficacy of pMDIs and DPIs for delivery of bronchodilator medications. However, some patients (eg, those with difficulty mastering the technique of pMDIs) may have a better response to a nebulizer. The decision to prescribe a nebulizer for home use is made on a case-by-case basis. Careful instructions are provided regarding indications for coming to the emergency department if one or two nebulizer treatments do not result in reduced symptoms.</p><p>Typically, jet nebulizers are provided for patients with asthma or COPD unless the patient is willing to pay extra for a smaller, more portable mesh nebulizer. For patients requiring specialized medications such as <a class="drug drug_general" data-topicid="9167" href="/z/d/drug information/9167.html" rel="external">budesonide</a> suspension, <a class="drug drug_general" data-topicid="8895" href="/z/d/drug information/8895.html" rel="external">iloprost</a>, <a class="drug drug_general" data-topicid="9752" href="/z/d/drug information/9752.html" rel="external">pentamidine</a>, <a class="drug drug_general" data-topicid="9860" href="/z/d/drug information/9860.html" rel="external">ribavirin</a>, DNase I, <a class="drug drug_general" data-topicid="10000" href="/z/d/drug information/10000.html" rel="external">tobramycin</a>, <a class="drug drug_general" data-topicid="9047" href="/z/d/drug information/9047.html" rel="external">aztreonam</a>, and <a class="drug drug_general" data-topicid="10207" href="/z/d/drug information/10207.html" rel="external">treprostinil</a> the selection of a nebulizer device depends on the requirements of the particular medication, as described above. (See <a class="local">'Nebulizers'</a> above.)</p><p>With a jet nebulizer, the patient also needs an air compressor in addition to the nebulizer, tubing, and mouthpiece. Although the nebulizer is disposable, many patients re-use it multiple times before replacing. Proper cleaning and air-drying of the nebulizer chamber and mouthpiece are needed to prevent bacterial and fungal colonization and also contamination by allergens, such as dust mites, cockroach, and dander. The plastic tubing and medication chamber should be stored in a plastic bag between uses. Once or twice a week, the nebulizer  (<a class="graphic graphic_figure graphicRef57284" href="/z/d/graphic/57284.html" rel="external">figure 1</a>) should be disassembled, washed in soapy tap water, and disinfected with either a 1.25 percent acetic acid (white vinegar) mixture or a quaternary ammonium compound at a dilution of 1 ounce to 1 gallon of sterile distilled water. The acetic acid soak should be at least 1 hour, but a quaternary ammonium compound soak needs only 10 minutes. However, patients with asthma should avoid breathing the fumes of these cleaning agents.</p><p>Ultrasonic and mesh nebulizers should be cleaned and disinfected per the manufacturer’s specifications. Acetic acid should not be reused, but the quaternary ammonium solution can be reused for up to one week.</p><p class="headingAnchor" id="H2277356178"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/110267.html" rel="external">"Society guideline links: Chronic obstructive pulmonary disease"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/112325.html" rel="external">"Society guideline links: Asthma in adolescents and adults"</a>.)</p><p class="headingAnchor" id="H23"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, “The Basics” and “Beyond the Basics.” The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on “patient info” and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/16114.html" rel="external">"Patient education: How to use your dry powder inhaler (adults) (The Basics)"</a> and  <a class="medical medical_basics" href="/z/d/html/16113.html" rel="external">"Patient education: How to use your metered dose inhaler (adults) (The Basics)"</a> and  <a class="medical medical_basics" href="/z/d/html/116647.html" rel="external">"Patient education: How to use your soft mist inhaler (adults) (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/z/d/html/1222.html" rel="external">"Patient education: Asthma symptoms and diagnosis in children (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/z/d/html/369.html" rel="external">"Patient education: Inhaler techniques in adults (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H24"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="headingAnchor" id="H25"><span class="h2">Available devices</span></p><p class="bulletIndent1"><span class="glyph">●</span>Four principal types of devices are used to deliver inhaled medications: pressurized metered dose inhalers (pMDIs), dry powder inhalers (DPIs), soft mist inhalers (SMIs), and nebulizers. A comparison of delivery devices for inhaled medications is provided in the table  (<a class="graphic graphic_table graphicRef71527" href="/z/d/graphic/71527.html" rel="external">table 1</a>). (See <a class="local">'Overview'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A pMDI consists of a pressurized canister, a metering valve and stem, and a mouthpiece actuator  (<a class="graphic graphic_figure graphicRef61575" href="/z/d/graphic/61575.html" rel="external">figure 5</a>) [<a href="#rid20">20</a>]. DPIs create aerosols by drawing air through a dose of powdered medication  (<a class="graphic graphic_picture graphicRef57922" href="/z/d/graphic/57922.html" rel="external">picture 3</a>). SMIs produce a fine particle, slow moving aerosol  (<a class="graphic graphic_picture graphicRef91634" href="/z/d/graphic/91634.html" rel="external">picture 12</a>). The correct techniques for using pMDIs, DPIs, and SMIs are reviewed separately. (See <a class="local">'Pressurized metered dose inhalers (pMDI)'</a> above and  <a class="medical medical_review" href="/z/d/html/559.html" rel="external">"The use of inhaler devices in adults"</a> and  <a class="medical medical_review" href="/z/d/html/5738.html" rel="external">"The use of inhaler devices in children"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The most commonly-used type of nebulizer is the jet (or pneumatic) nebulizer  (<a class="graphic graphic_figure graphicRef57284" href="/z/d/graphic/57284.html" rel="external">figure 1</a>); mesh and ultrasonic nebulizers are also available. Nebulizer performance is affected by technical factors, such as mechanism of aerosol generation and drug formulation (not all medications can be used with all nebulizers), as well as patient-related factors  (<a class="graphic graphic_table graphicRef58515" href="/z/d/graphic/58515.html" rel="external">table 9</a>). (See <a class="local">'Nebulizers'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>With all of the standard nebulizers, patients should be encouraged to use a slow breathing pattern with an occasional deep breath. We generally favor the use of mouthpieces over face masks, as the latter are associated with some facial and eye deposition of aerosol. (See <a class="local">'Mouthpieces and facemasks'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Mesh nebulizers force a solution or suspension of medication through a mesh to produce an aerosol, without need for an internal baffling system or compressed air source. These devices are quiet, portable, and able to generate aerosols with a high fine-particle fraction, resulting in more efficient drug delivery. (See <a class="local">'Mesh nebulizers'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Ultrasonic nebulizers transmit ultrasonic waves to the surface of the solution to create an aerosol, which is delivered to the patient by a fan or by the inspiratory flow generated by the patient’s breath. They are quieter than jet nebulizers, but cannot be used to deliver a drug in suspension. (See <a class="local">'Ultrasonic nebulizers'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Newer nebulizer designs to reduce drug wastage include breath-actuated devices that deliver the majority of the medication during inhalation and storage bag nebulizers. (See <a class="local">'Enhanced nebulizer designs'</a> above.)</p><p></p><p class="headingAnchor" id="H26"><span class="h2">Options for specific patient situations</span></p><p class="bulletIndent1"><span class="glyph">●</span>For spontaneously breathing patients, pMDIs, DPIs, and nebulizers are all effective for treatment of asthma and chronic obstructive pulmonary disease (COPD) when used correctly. Thus, we advise selecting a delivery device based upon the desired beta agonist or glucocorticoid, convenience, cost, clinician and patient preferences, and the patient’s ability to use the device correctly  (<a class="graphic graphic_table graphicRef71527" href="/z/d/graphic/71527.html" rel="external">table 1</a>). (See <a class="local">'Overview'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with a mild to moderate exacerbation of asthma, beta-2 agonists (eg, <a class="drug drug_general" data-topicid="9396" href="/z/d/drug information/9396.html" rel="external">albuterol</a>) may be administered either by nebulizer or by pMDI combined with a spacer or chamber device. For patients with a severe exacerbation of asthma not requiring mechanical ventilation, we suggest delivery of inhaled beta-2 agonists by nebulizer rather than pMDI (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Use of a nebulizer for a severe asthma exacerbation may be intermittent (every 20 to 30 minutes) or continuous. The doses of beta-2 agonists for these applications are provided in the table  (<a class="graphic graphic_table graphicRef72467" href="/z/d/graphic/72467.html" rel="external">table 2</a>). (See <a class="local">'Asthma exacerbation'</a> above and <a class="local">'Continuous nebulization'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Some drug preparations are only approved for delivery with specific nebulizers due to factors such as preventing contamination of the ambient environment, achieving greater precision in dosing, or preventing medication degradation by the aerosol technology. Examples of medications requiring specific nebulizers include <a class="drug drug_general" data-topicid="9167" href="/z/d/drug information/9167.html" rel="external">budesonide</a>, <a class="drug drug_general" data-topicid="8895" href="/z/d/drug information/8895.html" rel="external">iloprost</a>, <a class="drug drug_general" data-topicid="9752" href="/z/d/drug information/9752.html" rel="external">pentamidine</a>, <a class="drug drug_general" data-topicid="9860" href="/z/d/drug information/9860.html" rel="external">ribavirin</a>, DNase I, <a class="drug drug_general" data-topicid="10000" href="/z/d/drug information/10000.html" rel="external">tobramycin</a>, <a class="drug drug_general" data-topicid="9047" href="/z/d/drug information/9047.html" rel="external">aztreonam</a>, <a class="drug drug_general" data-topicid="10207" href="/z/d/drug information/10207.html" rel="external">treprostinil</a>, and liposomal <a class="drug drug_general" data-topicid="8536" href="/z/d/drug information/8536.html" rel="external">amikacin</a>  (<a class="graphic graphic_table graphicRef83376" href="/z/d/graphic/83376.html" rel="external">table 12</a>). (See <a class="local">'Nebulizers for specific medications'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Administration of medication aerosols by pMDI or nebulizer to a spontaneously breathing patient with a tracheostomy tube requires use of adaptive devices; examples are provided in the figure  (<a class="graphic graphic_picture graphicRef70613" href="/z/d/graphic/70613.html" rel="external">picture 6</a>). (See <a class="local">'Patients with tracheostomy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For mechanically-ventilated patients who require aerosol medication, we suggest the use of pMDIs, combined with a specialized spacer that is placed in the ventilator tubing  (<a class="graphic graphic_picture graphicRef53295" href="/z/d/graphic/53295.html" rel="external">picture 7</a>), or a mesh nebulizer, rather than a jet nebulizer (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). The pMDI method is technically easier than jet nebulizer treatments, involves less personnel time, provides a reliable dose of the drug, and reduces the risk of bacterial contamination that can occur with a nebulizer. Inhaled medications can also be delivered effectively to patients receiving noninvasive positive pressure ventilation (NIV). (See <a class="local">'Mechanically ventilated patients'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Accumulating evidence supports the use of a nebulizer for aerosol delivery with high flow nasal cannula. (See <a class="local">'Patients using high flow nasal cannula'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Hess DR. Aerosol delivery devices in the treatment of asthma. Respir Care 2008; 53:699.</a></li><li><a class="nounderline abstract_t">Laube BL, Janssens HM, de Jongh FH, et al. What the pulmonary specialist should know about the new inhalation therapies. Eur Respir J 2011; 37:1308.</a></li><li><a class="nounderline abstract_t">Dolovich MB, Dhand R. Aerosol drug delivery: developments in device design and clinical use. Lancet 2011; 377:1032.</a></li><li><a class="nounderline abstract_t">Olschewski H, Simonneau G, Galiè N, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002; 347:322.</a></li><li><a class="nounderline abstract_t">Furyk JS, Grabowski WJ, Black LH. Nebulized fentanyl versus intravenous morphine in children with suspected limb fractures in the emergency department: a randomized controlled trial. Emerg Med Australas 2009; 21:203.</a></li><li><a class="nounderline abstract_t">Krajnik M, Podolec Z, Siekierka M, et al. Morphine inhalation by cancer patients: a comparison of different nebulization techniques using pharmacokinetic, spirometric, and gasometric parameters. J Pain Symptom Manage 2009; 38:747.</a></li><li><a class="nounderline abstract_t">Nejmi H, Fath K, Anaflous R, et al. [A prospective randomized comparison of nebulized morphine versus thoracic epidural analgesia in the management of thoracic trauma]. Ann Fr Anesth Reanim 2010; 29:415.</a></li><li><a class="nounderline abstract_t">Dolovich MB, Ahrens RC, Hess DR, et al. Device selection and outcomes of aerosol therapy: Evidence-based guidelines: American College of Chest Physicians/American College of Asthma, Allergy, and Immunology. Chest 2005; 127:335.</a></li><li><a class="nounderline abstract_t">Brocklebank D, Wright J, Cates C. Systematic review of clinical effectiveness of pressurised metered dose inhalers versus other hand held inhaler devices for delivering corticosteroids in asthma. BMJ 2001; 323:896.</a></li><li><a class="nounderline abstract_t">Brocklebank D, Ram F, Wright J, et al. Comparison of the effectiveness of inhaler devices in asthma and chronic obstructive airways disease: a systematic review of the literature. Health Technol Assess 2001; 5:1.</a></li><li><a class="nounderline abstract_t">Turner MO, Patel A, Ginsburg S, FitzGerald JM. Bronchodilator delivery in acute airflow obstruction. A meta-analysis. Arch Intern Med 1997; 157:1736.</a></li><li><a class="nounderline abstract_t">Cates CJ, Crilly JA, Rowe BH. Holding chambers (spacers) versus nebulisers for beta-agonist treatment of acute asthma. Cochrane Database Syst Rev 2006; :CD000052.</a></li><li><a class="nounderline abstract_t">Frei SP. Cost comparison of bronchodilator delivery methods in Emergency Department treatment of asthma. J Emerg Med 2000; 19:323.</a></li><li><a class="nounderline abstract_t">Turner MO, Gafni A, Swan D, FitzGerald JM. A review and economic evaluation of bronchodilator delivery methods in hospitalized patients. Arch Intern Med 1996; 156:2113.</a></li><li><a class="nounderline abstract_t">Ram FS, Wright J, Brocklebank D, White JE. Systematic review of clinical effectiveness of pressurised metered dose inhalers versus other hand held inhaler devices for delivering beta (2 )agonists bronchodilators in asthma. BMJ 2001; 323:901.</a></li><li class="breakAll">National Asthma Education and Prevention Program. Expert panel report III: Guidelines for the diagnosis and management of asthma. National Heart, Lung, and Blood Institute (NIH publication no. 08-4051), Bethesda, MD 2007, www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm (Accessed on March 21, 2011).</li><li><a class="nounderline abstract_t">Dugernier J, Hesse M, Jumetz T, et al. Aerosol Delivery with Two Nebulizers Through High-Flow Nasal Cannula: A Randomized Cross-Over Single-Photon Emission Computed Tomography-Computed Tomography Study. J Aerosol Med Pulm Drug Deliv 2017; 30:349.</a></li><li><a class="nounderline abstract_t">Bosnic-Anticevich S, Chrystyn H, Costello RW, et al. The use of multiple respiratory inhalers requiring different inhalation techniques has an adverse effect on COPD outcomes. Int J Chron Obstruct Pulmon Dis 2017; 12:59.</a></li><li><a class="nounderline abstract_t">Price D, Chrystyn H, Kaplan A, et al. Effectiveness of same versus mixed asthma inhaler devices: a retrospective observational study in primary care. Allergy Asthma Immunol Res 2012; 4:184.</a></li><li><a class="nounderline abstract_t">Newman SP. Principles of metered-dose inhaler design. Respir Care 2005; 50:1177.</a></li><li><a class="nounderline abstract_t">Hendeles L, Colice GL, Meyer RJ. Withdrawal of albuterol inhalers containing chlorofluorocarbon propellants. N Engl J Med 2007; 356:1344.</a></li><li><a class="nounderline abstract_t">Leach CL, Davidson PJ, Boudreau RJ. Improved airway targeting with the CFC-free HFA-beclomethasone metered-dose inhaler compared with CFC-beclomethasone. Eur Respir J 1998; 12:1346.</a></li><li><a class="nounderline abstract_t">Gross G, Thompson PJ, Chervinsky P, Vanden Burgt J. Hydrofluoroalkane-134a beclomethasone dipropionate, 400 microg, is as effective as chlorofluorocarbon beclomethasone dipropionate, 800 microg, for the treatment of moderate asthma. Chest 1999; 115:343.</a></li><li><a class="nounderline abstract_t">Ferguson GT, Hickey AJ, Dwivedi S. Co-suspension delivery technology in pressurized metered-dose inhalers for multi-drug dosing in the treatment of respiratory diseases. Respir Med 2018; 134:16.</a></li><li><a class="nounderline abstract_t">McFadden ER Jr. Improper patient techniques with metered dose inhalers: clinical consequences and solutions to misuse. J Allergy Clin Immunol 1995; 96:278.</a></li><li><a class="nounderline abstract_t">Murphy KR, Dhand R, Trudo F, et al. Therapeutic equivalence of budesonide/formoterol delivered via breath-actuated inhaler vs pMDI. Respir Med 2015; 109:170.</a></li><li><a class="nounderline abstract_t">Langley PC. The technology of metered-dose inhalers and treatment costs in asthma: a retrospective study of breath actuation versus traditional press-and-breathe inhalers. Clin Ther 1999; 21:236.</a></li><li><a class="nounderline abstract_t">Fink JB. Metered-dose inhalers, dry powder inhalers, and transitions. Respir Care 2000; 45:623.</a></li><li><a class="nounderline abstract_t">Newman SP, Busse WW. Evolution of dry powder inhaler design, formulation, and performance. Respir Med 2002; 96:293.</a></li><li><a class="nounderline abstract_t">Atkins PJ. Dry powder inhalers: an overview. Respir Care 2005; 50:1304.</a></li><li><a class="nounderline abstract_t">Clark AR, Hollingworth AM. The relationship between powder inhaler resistance and peak inspiratory conditions in healthy volunteers--implications for in vitro testing. J Aerosol Med 1993; 6:99.</a></li><li><a class="nounderline abstract_t">Weers J, Clark A. The Impact of Inspiratory Flow Rate on Drug Delivery to the Lungs with Dry Powder Inhalers. Pharm Res 2017; 34:507.</a></li><li><a class="nounderline abstract_t">Clark AR, Weers JG, Dhand R. The Confusing World of Dry Powder Inhalers: It Is All About Inspiratory Pressures, Not Inspiratory Flow Rates. J Aerosol Med Pulm Drug Deliv 2020; 33:1.</a></li><li><a class="nounderline abstract_t">Srichana T, Martin GP, Marriott C. Dry powder inhalers: the influence of device resistance and powder formulation on drug and lactose deposition in vitro. Eur J Pharm Sci 1998; 7:73.</a></li><li><a class="nounderline abstract_t">Bentur L, Mansour Y, Hamzani Y, et al. Measurement of inspiratory flow in children with acute asthma. Pediatr Pulmonol 2004; 38:304.</a></li><li><a class="nounderline abstract_t">Azouz W, Chetcuti P, Hosker HS, et al. The inhalation characteristics of patients when they use different dry powder inhalers. J Aerosol Med Pulm Drug Deliv 2015; 28:35.</a></li><li><a class="nounderline abstract_t">Brown PH, Ning AC, Greening AP, et al. Peak inspiratory flow through Turbuhaler in acute asthma. Eur Respir J 1995; 8:1940.</a></li><li><a class="nounderline abstract_t">Dalby R, Spallek M, Voshaar T. A review of the development of Respimat Soft Mist Inhaler. Int J Pharm 2004; 283:1.</a></li><li><a class="nounderline abstract_t">Hochrainer D, Hölz H, Kreher C, et al. Comparison of the aerosol velocity and spray duration of Respimat Soft Mist inhaler and pressurized metered dose inhalers. J Aerosol Med 2005; 18:273.</a></li><li><a class="nounderline abstract_t">Newman SP, Brown J, Steed KP, et al. Lung deposition of fenoterol and flunisolide delivered using a novel device for inhaled medicines: comparison of RESPIMAT with conventional metered-dose inhalers with and without spacer devices. Chest 1998; 113:957.</a></li><li><a class="nounderline abstract_t">Newman SP, Steed KP, Reader SJ, et al. Efficient delivery to the lungs of flunisolide aerosol from a new portable hand-held multidose nebulizer. J Pharm Sci 1996; 85:960.</a></li><li><a class="nounderline abstract_t">Kunkel G, Magnussen H, Bergmann K, et al. Respimat (a new soft mist inhaler) delivering fenoterol plus ipratropium bromide provides equivalent bronchodilation at half the cumulative dose compared with a conventional metered dose inhaler in asthmatic patients. Respiration 2000; 67:306.</a></li><li><a class="nounderline abstract_t">Hess DR. Nebulizers: principles and performance. Respir Care 2000; 45:609.</a></li><li><a class="nounderline abstract_t">Rau JL. Design principles of liquid nebulization devices currently in use. Respir Care 2002; 47:1257.</a></li><li><a class="nounderline abstract_t">Leung K, Louca E, Coates AL. Comparison of breath-enhanced to breath-actuated nebulizers for rate, consistency, and efficiency. Chest 2004; 126:1619.</a></li><li><a class="nounderline abstract_t">Hess D, Fisher D, Williams P, et al. Medication nebulizer performance. Effects of diluent volume, nebulizer flow, and nebulizer brand. Chest 1996; 110:498.</a></li><li><a class="nounderline abstract_t">Fink JB. Aerosol device selection: evidence to practice. Respir Care 2000; 45:874.</a></li><li><a class="nounderline abstract_t">Burchett DK, Darko W, Zahra J, et al. Mixing and compatibility guide for commonly used aerosolized medications. Am J Health Syst Pharm 2010; 67:227.</a></li><li><a class="nounderline abstract_t">Camargo CA Jr, Rachelefsky G, Schatz M. Managing asthma exacerbations in the emergency department: summary of the National Asthma Education And Prevention Program Expert Panel Report 3 guidelines for the management of asthma exacerbations. Proc Am Thorac Soc 2009; 6:357.</a></li><li><a class="nounderline abstract_t">Standaert TA, Vandevanter D, Ramsey BW, et al. The choice of compressor effects the aerosol parameters and the delivery of tobramycin from a single model nebulizer. J Aerosol Med 2000; 13:147.</a></li><li><a class="nounderline abstract_t">Standaert TA, Bohn SE, Aitken ML, Ramsey B. The equivalence of compressor pressure-flow relationships with respect to jet nebulizer aerosolization characteristics. J Aerosol Med 2001; 14:31.</a></li><li><a class="nounderline abstract_t">Reisner C, Katial RK, Bartelson BB, et al. Characterization of aerosol output from various nebulizer/compressor combinations. Ann Allergy Asthma Immunol 2001; 86:566.</a></li><li><a class="nounderline abstract_t">Hess DR, Acosta FL, Ritz RH, et al. The effect of heliox on nebulizer function using a beta-agonist bronchodilator. Chest 1999; 115:184.</a></li><li><a class="nounderline abstract_t">Kress JP, Noth I, Gehlbach BK, et al. The utility of albuterol nebulized with heliox during acute asthma exacerbations. Am J Respir Crit Care Med 2002; 165:1317.</a></li><li><a class="nounderline abstract_t">Henderson SO, Acharya P, Kilaghbian T, et al. Use of heliox-driven nebulizer therapy in the treatment of acute asthma. Ann Emerg Med 1999; 33:141.</a></li><li><a class="nounderline abstract_t">Anderson M, Svartengren M, Philipson K, et al. Deposition in man of particles suspended in air or in helium-oxygen mixture at different flow rates. J Aerosol Med 1990; 3:209.</a></li><li><a class="nounderline abstract_t">Anderson M, Svartengren M, Bylin G, et al. Deposition in asthmatics of particles inhaled in air or in helium-oxygen. Am Rev Respir Dis 1993; 147:524.</a></li><li><a class="nounderline abstract_t">Habib DM, Garner SS, Brandeburg S. Effect of helium-oxygen on delivery of albuterol in a pediatric, volume-cycled, ventilated lung model. Pharmacotherapy 1999; 19:143.</a></li><li><a class="nounderline abstract_t">Svartengren M, Anderson M, Philipson K, Camner P. Human lung deposition of particles suspended in air or in helium/oxygen mixture. Exp Lung Res 1989; 15:575.</a></li><li><a class="nounderline abstract_t">Smith EC, Denyer J, Kendrick AH. Comparison of twenty three nebulizer/compressor combinations for domiciliary use. Eur Respir J 1995; 8:1214.</a></li><li><a class="nounderline abstract_t">Kendrick AH, Smith EC, Wilson RS. Selecting and using nebuliser equipment. Thorax 1997; 52 Suppl 2:S92.</a></li><li><a class="nounderline abstract_t">Berlinski A, Waldrep JC. Four hours of continuous albuterol nebulization. Chest 1998; 114:847.</a></li><li><a class="nounderline abstract_t">Gulley SL, Baltzley SM, Junkins AD, et al. Sterility and Stability Testing of Preservative-free Albuterol. J Pediatr Pharmacol Ther 2019; 24:53.</a></li><li><a class="nounderline abstract_t">Pertzborn MC, Prabhakaran S, Abu-Hasan M, et al. Continuous Albuterol With Benzalkonium in Children Hospitalized With Severe Asthma. Pediatrics 2020; 145.</a></li><li><a class="nounderline abstract_t">The Medical Letter. Large-Volume, Preservative-Free Albuterol Concentrate. Med Lett Drugs Ther 2020; 62:173.</a></li><li><a class="nounderline abstract_t">Orth LE, Kelly BJ, Lagasse CA, et al. Safety and effectiveness of albuterol solutions with and without benzalkonium chloride when administered by continuous nebulization. Am J Health Syst Pharm 2018; 75:1791.</a></li><li><a class="nounderline abstract_t">Woolf AD, Manzi SF. Benzalkonium Chloride in Albuterol Solutions: Time for a Change? Pediatrics 2020; 145.</a></li><li><a class="nounderline abstract_t">McPeck M, Tandon R, Hughes K, Smaldone GC. Aerosol delivery during continuous nebulization. Chest 1997; 111:1200.</a></li><li><a class="nounderline abstract_t">Reisner C, Lee J, Kotch A, Dworkin G. Comparison of volume output from two different continuous nebulizer systems. Ann Allergy Asthma Immunol 1996; 76:209.</a></li><li><a class="nounderline abstract_t">Berlinski A, Willis JR, Leisenring T. In-vitro comparison of 4 large-volume nebulizers in 8 hours of continuous nebulization. Respir Care 2010; 55:1671.</a></li><li><a class="nounderline abstract_t">Hess DR. Aerosol Therapy During Noninvasive Ventilation or High-Flow Nasal Cannula. Respir Care 2015; 60:880.</a></li><li><a class="nounderline abstract_t">Réminiac F, Vecellio L, Heuzé-Vourc'h N, et al. Aerosol Therapy in Adults Receiving High Flow Nasal Cannula Oxygen Therapy. J Aerosol Med Pulm Drug Deliv 2016; 29:134.</a></li><li><a class="nounderline abstract_t">Dhand R. New frontiers in aerosol delivery during mechanical ventilation. Respir Care 2004; 49:666.</a></li><li><a class="nounderline abstract_t">Waldrep JC, Dhand R. Advanced nebulizer designs employing vibrating mesh/aperture plate technologies for aerosol generation. Curr Drug Deliv 2008; 5:114.</a></li><li><a class="nounderline abstract_t">Hardaker LE, Hatley RH. In vitro characterization of the I-neb Adaptive Aerosol Delivery (AAD) system. J Aerosol Med Pulm Drug Deliv 2010; 23 Suppl 1:S11.</a></li><li><a class="nounderline abstract_t">Denyer J, Dyche T. The Adaptive Aerosol Delivery (AAD) technology: Past, present, and future. J Aerosol Med Pulm Drug Deliv 2010; 23 Suppl 1:S1.</a></li><li><a class="nounderline abstract_t">Skaria S, Smaldone GC. Omron NE U22: Comparison between vibrating mesh and jet nebulizer. J Aerosol Med Pulm Drug Deliv 2010; 23:173.</a></li><li><a class="nounderline abstract_t">Gowda AA, Cuccia AD, Smaldone GC. Reliability of Vibrating Mesh Technology. Respir Care 2017; 62:65.</a></li><li><a class="nounderline abstract_t">Yeo LY, Friend JR, McIntosh MP, et al. Ultrasonic nebulization platforms for pulmonary drug delivery. Expert Opin Drug Deliv 2010; 7:663.</a></li><li><a class="nounderline abstract_t">Berger W. Aerosol devices and asthma therapy. Curr Drug Deliv 2009; 6:38.</a></li><li><a class="nounderline abstract_t">Rau JL, Ari A, Restrepo RD. Performance comparison of nebulizer designs: constant-output, breath-enhanced, and dosimetric. Respir Care 2004; 49:174.</a></li><li><a class="nounderline abstract_t">Sabato K, Ward P, Hawk W, et al. Randomized controlled trial of a breath-actuated nebulizer in pediatric asthma patients in the emergency department. Respir Care 2011; 56:761.</a></li><li><a class="nounderline abstract_t">Sangwan S, Gurses BK, Smaldone GC. Facemasks and facial deposition of aerosols. Pediatr Pulmonol 2004; 37:447.</a></li><li><a class="nounderline abstract_t">Simonds AK, Hanak A, Chatwin M, et al. Evaluation of droplet dispersion during non-invasive ventilation, oxygen therapy, nebuliser treatment and chest physiotherapy in clinical practice: implications for management of pandemic influenza and other airborne infections. Health Technol Assess 2010; 14:131.</a></li><li><a class="nounderline abstract_t">O'Neil CA, Li J, Leavey A, et al. Characterization of Aerosols Generated During Patient Care Activities. Clin Infect Dis 2017; 65:1335.</a></li><li><a class="nounderline abstract_t">Tran K, Cimon K, Severn M, et al. Aerosol generating procedures and risk of transmission of acute respiratory infections to healthcare workers: a systematic review. PLoS One 2012; 7:e35797.</a></li><li><a class="nounderline abstract_t">Hui DS, Chan MT, Chow B. Aerosol dispersion during various respiratory therapies: a risk assessment model of nosocomial infection to health care workers. Hong Kong Med J 2014; 20 Suppl 4:9.</a></li><li><a class="nounderline abstract_t">Jones RM, Brosseau LM. Aerosol transmission of infectious disease. J Occup Environ Med 2015; 57:501.</a></li><li class="breakAll">https://www.cdc.gov/coronavirus/2019-ncov/faq.html (Accessed on November 20, 2020).</li><li class="breakAll">https://www.who.int/publications/i/item/WHO-2019-nCoV-IPC-2020.4 (Accessed on November 20, 2020).</li><li><a class="nounderline abstract_t">Dhand R, Li J. Coughs and Sneezes: Their Role in Transmission of Respiratory Viral Infections, Including SARS-CoV-2. Am J Respir Crit Care Med 2020; 202:651.</a></li><li><a class="nounderline abstract_t">Fink JB, Ehrmann S, Li J, et al. Reducing Aerosol-Related Risk of Transmission in the Era of COVID-19: An Interim Guidance Endorsed by the International Society of Aerosols in Medicine. J Aerosol Med Pulm Drug Deliv 2020; 33:300.</a></li><li class="breakAll">Centers for Disease Control and Prevention. Interim Infection Prevention and Control Recommendations for Patients with Confirmed 2019 Novel Coronavirus (2019-nCoV) or Patients Under Investigation for 2019-nCoV in Healthcare Settings https://www.cdc.gov/coronavirus/2019-nCoV/hcp/infection-control.html (Accessed on July 19, 2020).</li><li class="breakAll">World Health Organization. Infection prevention and control during health care when novel coronavirus (nCoV) infection is suspected. https://www.who.int/publications/i/item/infection-prevention-and-control-during-health-care-when-novel-coronavirus-(ncov)-infection-is-suspected-20200125 (Accessed on July 19, 2020).</li><li class="breakAll">Infectious Diseases Society of America guidelines on infection prevention for health care personnel caring for patients with suspected or known COVID-19. https://www.idsociety.org/COVID19guidelines/ip (Accessed on July 19, 2020).</li><li><a class="nounderline abstract_t">Coates AL, MacNeish CF, Meisner D, et al. The choice of jet nebulizer, nebulizing flow, and addition of albuterol affects the output of tobramycin aerosols. Chest 1997; 111:1206.</a></li><li><a class="nounderline abstract_t">MacNeish CF, Meisner D, Thibert R, et al. A comparison of pulmonary availability between Ventolin (albuterol) nebules and Ventolin (albuterol) Respirator Solution. Chest 1997; 111:204.</a></li><li><a class="nounderline abstract_t">Flament MP, Leterme P, Burnouf T, Gayot A. Influence of formulation on jet nebulisation quality of alpha 1 protease inhibitor. Int J Pharm 1999; 178:101.</a></li><li><a class="nounderline abstract_t">Hess DR. Liquid nebulization: emerging technologies conference summary. Respir Care 2002; 47:1471.</a></li><li><a class="nounderline abstract_t">Smaldone GC. Assessing new technologies: patient-device interactions and deposition. Respir Care 2005; 50:1151.</a></li><li><a class="nounderline abstract_t">Dhand R. Intelligent nebulizers in the age of the Internet: The I-neb Adaptive Aerosol Delivery (AAD) system. J Aerosol Med Pulm Drug Deliv 2010; 23 Suppl 1:iii.</a></li><li><a class="nounderline abstract_t">Ferguson GT, Feldman G, Pudi KK, et al. Improvements in Lung Function with Nebulized Revefenacin in the Treatment of Patients with Moderate to Very Severe COPD: Results from Two Replicate Phase III Clinical Trials. Chronic Obstr Pulm Dis 2019; 6:154.</a></li><li><a class="nounderline abstract_t">Heo YA. Revefenacin: First Global Approval. Drugs 2019; 79:85.</a></li><li><a class="nounderline abstract_t">Shirley M. Amikacin Liposome Inhalation Suspension: A Review in Mycobacterium avium Complex Lung Disease. Drugs 2019; 79:555.</a></li><li><a class="nounderline abstract_t">Daley CL, Iaccarino JM, Lange C, et al. Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline. Clin Infect Dis 2020; 71:905.</a></li><li><a class="nounderline abstract_t">Camargo CA Jr, Spooner CH, Rowe BH. Continuous versus intermittent beta-agonists in the treatment of acute asthma. Cochrane Database Syst Rev 2003; :CD001115.</a></li><li><a class="nounderline abstract_t">Peters SG. Continuous bronchodilator therapy. Chest 2007; 131:286.</a></li><li><a class="nounderline abstract_t">Salo D, Tuel M, Lavery RF, et al. A randomized, clinical trial comparing the efficacy of continuous nebulized albuterol (15 mg) versus continuous nebulized albuterol (15 mg) plus ipratropium bromide (2 mg) for the treatment of acute asthma. J Emerg Med 2006; 31:371.</a></li><li><a class="nounderline abstract_t">Rodrigo GJ, Rodrigo C. Continuous vs intermittent beta-agonists in the treatment of acute adult asthma: a systematic review with meta-analysis. Chest 2002; 122:160.</a></li><li><a class="nounderline abstract_t">Zitek T, Cleveland N, Rahbar A, et al. Effect of Nebulized Albuterol on Serum Lactate and Potassium in Healthy Subjects. Acad Emerg Med 2016; 23:718.</a></li><li><a class="nounderline abstract_t">Piccuito CM, Hess DR. Albuterol delivery via tracheostomy tube. Respir Care 2005; 50:1071.</a></li><li><a class="nounderline abstract_t">Berlinski A, Ari A, Davies P, et al. Workshop Report: Aerosol Delivery to Spontaneously Breathing Tracheostomized Patients. J Aerosol Med Pulm Drug Deliv 2017; 30:207.</a></li><li><a class="nounderline abstract_t">Hess D. Aerosol delivery during mechanical ventilation. Minerva Anestesiol 2002; 68:321.</a></li><li><a class="nounderline abstract_t">Miller DD, Amin MM, Palmer LB, et al. Aerosol delivery and modern mechanical ventilation: in vitro/in vivo evaluation. Am J Respir Crit Care Med 2003; 168:1205.</a></li><li><a class="nounderline abstract_t">Georgopoulos D, Mouloudi E, Kondili E, Klimathianaki M. Bronchodilator delivery with metered-dose inhaler during mechanical ventilation. Crit Care 2000; 4:227.</a></li><li><a class="nounderline abstract_t">Dhand R. Aerosol delivery during mechanical ventilation: from basic techniques to new devices. J Aerosol Med Pulm Drug Deliv 2008; 21:45.</a></li><li><a class="nounderline abstract_t">Dhand R, Guntur VP. How best to deliver aerosol medications to mechanically ventilated patients. Clin Chest Med 2008; 29:277.</a></li><li><a class="nounderline abstract_t">Ari A, Atalay OT, Harwood R, et al. Influence of nebulizer type, position, and bias flow on aerosol drug delivery in simulated pediatric and adult lung models during mechanical ventilation. Respir Care 2010; 55:845.</a></li><li><a class="nounderline abstract_t">Guerin C, Fassier T, Bayle F, et al. Inhaled bronchodilator administration during mechanical ventilation: how to optimize it, and for which clinical benefit? J Aerosol Med Pulm Drug Deliv 2008; 21:85.</a></li><li><a class="nounderline abstract_t">Dhand R. Basic techniques for aerosol delivery during mechanical ventilation. Respir Care 2004; 49:611.</a></li><li><a class="nounderline abstract_t">Ari A, Areabi H, Fink JB. Evaluation of aerosol generator devices at 3 locations in humidified and non-humidified circuits during adult mechanical ventilation. Respir Care 2010; 55:837.</a></li><li><a class="nounderline abstract_t">Dhand R, Sohal H. Pulmonary Drug Delivery System for inhalation therapy in mechanically ventilated patients. Expert Rev Med Devices 2008; 5:9.</a></li><li><a class="nounderline abstract_t">Dhand R. Inhalation therapy in invasive and noninvasive mechanical ventilation. Curr Opin Crit Care 2007; 13:27.</a></li><li><a class="nounderline abstract_t">Ari A, Fink JB, Dhand R. Inhalation therapy in patients receiving mechanical ventilation: an update. J Aerosol Med Pulm Drug Deliv 2012; 25:319.</a></li><li><a class="nounderline abstract_t">Dhand R, Duarte AG, Jubran A, et al. Dose-response to bronchodilator delivered by metered-dose inhaler in ventilator-supported patients. Am J Respir Crit Care Med 1996; 154:388.</a></li><li><a class="nounderline abstract_t">Lin HL, Fink JB, Zhou Y, Cheng YS. Influence of moisture accumulation in inline spacer on delivery of aerosol using metered-dose inhaler during mechanical ventilation. Respir Care 2009; 54:1336.</a></li><li><a class="nounderline abstract_t">Hess DR, Dillman C, Kacmarek RM. In vitro evaluation of aerosol bronchodilator delivery during mechanical ventilation: pressure-control vs. volume control ventilation. Intensive Care Med 2003; 29:1145.</a></li><li><a class="nounderline abstract_t">Dhand R, Tobin MJ. Inhaled bronchodilator therapy in mechanically ventilated patients. Am J Respir Crit Care Med 1997; 156:3.</a></li><li><a class="nounderline abstract_t">Goode ML, Fink JB, Dhand R, Tobin MJ. Improvement in aerosol delivery with helium-oxygen mixtures during mechanical ventilation. Am J Respir Crit Care Med 2001; 163:109.</a></li><li><a class="nounderline abstract_t">Tassaux D, Jolliet P, Thouret JM, et al. Calibration of seven ICU ventilators for mechanical ventilation with helium-oxygen mixtures. Am J Respir Crit Care Med 1999; 160:22.</a></li><li><a class="nounderline abstract_t">Devabhaktuni VG, Torres A Jr, Wilson S, Yeh MP. Effect of nitric oxide, perfluorocarbon, and heliox on minute volume measurement and ventilator volumes delivered. Crit Care Med 1999; 27:1603.</a></li><li><a class="nounderline abstract_t">Oppenheim-Eden A, Cohen Y, Weissman C, Pizov R. The effect of helium on ventilator performance: study of five ventilators and a bedside Pitot tube spirometer. Chest 2001; 120:582.</a></li><li><a class="nounderline abstract_t">Ari A, Alwadeai KS, Fink JB. Effects of Heat and Moisture Exchangers and Exhaled Humidity on Aerosol Deposition in a Simulated Ventilator-Dependent Adult Lung Model. Respir Care 2017; 62:538.</a></li><li><a class="nounderline abstract_t">Berlinski A, Willis JR. Albuterol delivery by 4 different nebulizers placed in 4 different positions in a pediatric ventilator in vitro model. Respir Care 2013; 58:1124.</a></li><li><a class="nounderline abstract_t">Marik P, Hogan J, Krikorian J. A comparison of bronchodilator therapy delivered by nebulization and metered-dose inhaler in mechanically ventilated patients. Chest 1999; 115:1653.</a></li><li><a class="nounderline abstract_t">Duarte AG, Momii K, Bidani A. Bronchodilator therapy with metered-dose inhaler and spacer versus nebulizer in mechanically ventilated patients: comparison of magnitude and duration of response. Respir Care 2000; 45:817.</a></li><li><a class="nounderline abstract_t">Ari A. Aerosol Therapy in Pulmonary Critical Care. Respir Care 2015; 60:858.</a></li><li><a class="nounderline abstract_t">Chatmongkolchart S, Schettino GP, Dillman C, et al. In vitro evaluation of aerosol bronchodilator delivery during noninvasive positive pressure ventilation: effect of ventilator settings and nebulizer position. Crit Care Med 2002; 30:2515.</a></li><li><a class="nounderline abstract_t">Branconnier MP, Hess DR. Albuterol delivery during noninvasive ventilation. Respir Care 2005; 50:1649.</a></li><li><a class="nounderline abstract_t">Hess DR. The mask for noninvasive ventilation: principles of design and effects on aerosol delivery. J Aerosol Med 2007; 20 Suppl 1:S85.</a></li><li><a class="nounderline abstract_t">Pollack CV Jr, Fleisch KB, Dowsey K. Treatment of acute bronchospasm with beta-adrenergic agonist aerosols delivered by a nasal bilevel positive airway pressure circuit. Ann Emerg Med 1995; 26:552.</a></li><li><a class="nounderline abstract_t">Dhand R. Aerosol therapy in patients receiving noninvasive positive pressure ventilation. J Aerosol Med Pulm Drug Deliv 2012; 25:63.</a></li><li><a class="nounderline abstract_t">Nava S, Karakurt S, Rampulla C, et al. Salbutamol delivery during non-invasive mechanical ventilation in patients with chronic obstructive pulmonary disease: a randomized, controlled study. Intensive Care Med 2001; 27:1627.</a></li><li><a class="nounderline abstract_t">Papazian L, Corley A, Hess D, et al. Use of high-flow nasal cannula oxygenation in ICU adults: a narrative review. Intensive Care Med 2016; 42:1336.</a></li><li><a class="nounderline abstract_t">Levy SD, Alladina JW, Hibbert KA, et al. High-flow oxygen therapy and other inhaled therapies in intensive care units. Lancet 2016; 387:1867.</a></li><li><a class="nounderline abstract_t">Li J, Fink JB, MacLoughlin R, Dhand R. A narrative review on trans-nasal pulmonary aerosol delivery. Crit Care 2020; 24:506.</a></li><li><a class="nounderline abstract_t">Bräunlich J, Wirtz H. Oral Versus Nasal High-Flow Bronchodilator Inhalation in Chronic Obstructive Pulmonary Disease. J Aerosol Med Pulm Drug Deliv 2018; 31:248.</a></li><li><a class="nounderline abstract_t">Li J, Zhao M, Hadeer M, et al. Dose Response to Transnasal Pulmonary Administration of Bronchodilator Aerosols via Nasal High-Flow Therapy in Adults with Stable Chronic Obstructive Pulmonary Disease and Asthma. Respiration 2019; 98:401.</a></li></ol></div><div id="topicVersionRevision">Topic 552 Version 39.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18501026" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Aerosol delivery devices in the treatment of asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21310878" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : What the pulmonary specialist should know about the new inhalation therapies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21036392" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Aerosol drug delivery: developments in device design and clinical use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12151469" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Inhaled iloprost for severe pulmonary hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19527280" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Nebulized fentanyl versus intravenous morphine in children with suspected limb fractures in the emergency department: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19783397" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Morphine inhalation by cancer patients: a comparison of different nebulization techniques using pharmacokinetic, spirometric, and gasometric parameters.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20537851" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : [A prospective randomized comparison of nebulized morphine versus thoracic epidural analgesia in the management of thoracic trauma].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15654001" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Device selection and outcomes of aerosol therapy: Evidence-based guidelines: American College of Chest Physicians/American College of Asthma, Allergy, and Immunology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11668133" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Systematic review of clinical effectiveness of pressurised metered dose inhalers versus other hand held inhaler devices for delivering corticosteroids in asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11701099" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Comparison of the effectiveness of inhaler devices in asthma and chronic obstructive airways disease: a systematic review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9250235" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Bronchodilator delivery in acute airflow obstruction. A meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16625527" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Holding chambers (spacers) versus nebulisers for beta-agonist treatment of acute asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11074323" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Cost comparison of bronchodilator delivery methods in Emergency Department treatment of asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8862104" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : A review and economic evaluation of bronchodilator delivery methods in hospitalized patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11668134" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Systematic review of clinical effectiveness of pressurised metered dose inhalers versus other hand held inhaler devices for delivering beta (2 )agonists bronchodilators in asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11668134" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Systematic review of clinical effectiveness of pressurised metered dose inhalers versus other hand held inhaler devices for delivering beta (2 )agonists bronchodilators in asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28463044" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Aerosol Delivery with Two Nebulizers Through High-Flow Nasal Cannula: A Randomized Cross-Over Single-Photon Emission Computed Tomography-Computed Tomography Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28053517" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : The use of multiple respiratory inhalers requiring different inhalation techniques has an adverse effect on COPD outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22754711" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Effectiveness of same versus mixed asthma inhaler devices: a retrospective observational study in primary care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16122401" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Principles of metered-dose inhaler design.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17392304" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Withdrawal of albuterol inhalers containing chlorofluorocarbon propellants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9877489" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Improved airway targeting with the CFC-free HFA-beclomethasone metered-dose inhaler compared with CFC-beclomethasone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10027430" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Hydrofluoroalkane-134a beclomethasone dipropionate, 400 microg, is as effective as chlorofluorocarbon beclomethasone dipropionate, 800 microg, for the treatment of moderate asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29413503" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Co-suspension delivery technology in pressurized metered-dose inhalers for multi-drug dosing in the treatment of respiratory diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7636071" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Improper patient techniques with metered dose inhalers: clinical consequences and solutions to misuse.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25596138" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Therapeutic equivalence of budesonide/formoterol delivered via breath-actuated inhaler vs pMDI.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10090438" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : The technology of metered-dose inhalers and treatment costs in asthma: a retrospective study of breath actuation versus traditional press-and-breathe inhalers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10894455" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Metered-dose inhalers, dry powder inhalers, and transitions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12113378" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Evolution of dry powder inhaler design, formulation, and performance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16185366" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Dry powder inhalers: an overview.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10146277" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : The relationship between powder inhaler resistance and peak inspiratory conditions in healthy volunteers--implications for in vitro testing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27738953" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : The Impact of Inspiratory Flow Rate on Drug Delivery to the Lungs with Dry Powder Inhalers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31613682" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : The Confusing World of Dry Powder Inhalers: It Is All About Inspiratory Pressures, Not Inspiratory Flow Rates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9845780" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Dry powder inhalers: the influence of device resistance and powder formulation on drug and lactose deposition in vitro.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15334507" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Measurement of inspiratory flow in children with acute asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24815999" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : The inhalation characteristics of patients when they use different dry powder inhalers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8620966" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Peak inspiratory flow through Turbuhaler in acute asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15363496" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : A review of the development of Respimat Soft Mist Inhaler.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16181002" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Comparison of the aerosol velocity and spray duration of Respimat Soft Mist inhaler and pressurized metered dose inhalers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9554631" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Lung deposition of fenoterol and flunisolide delivered using a novel device for inhaled medicines: comparison of RESPIMAT with conventional metered-dose inhalers with and without spacer devices.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8877887" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Efficient delivery to the lungs of flunisolide aerosol from a new portable hand-held multidose nebulizer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10867600" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Respimat (a new soft mist inhaler) delivering fenoterol plus ipratropium bromide provides equivalent bronchodilation at half the cumulative dose compared with a conventional metered dose inhaler in asthmatic patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10894454" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Nebulizers: principles and performance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12425742" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Design principles of liquid nebulization devices currently in use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15539736" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Comparison of breath-enhanced to breath-actuated nebulizers for rate, consistency, and efficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8697857" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Medication nebulizer performance. Effects of diluent volume, nebulizer flow, and nebulizer brand.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10926386" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Aerosol device selection: evidence to practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20101066" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Mixing and compatibility guide for commonly used aerosolized medications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19675345" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Managing asthma exacerbations in the emergency department: summary of the National Asthma Education And Prevention Program Expert Panel Report 3 guidelines for the management of asthma exacerbations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11010595" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : The choice of compressor effects the aerosol parameters and the delivery of tobramycin from a single model nebulizer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11495483" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : The equivalence of compressor pressure-flow relationships with respect to jet nebulizer aerosolization characteristics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11379809" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Characterization of aerosol output from various nebulizer/compressor combinations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9925082" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : The effect of heliox on nebulizer function using a beta-agonist bronchodilator.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11991886" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : The utility of albuterol nebulized with heliox during acute asthma exacerbations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9922408" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Use of heliox-driven nebulizer therapy in the treatment of acute asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Deposition in man of particles suspended in air or in helium-oxygen mixture at different flow rates</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8442582" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Deposition in asthmatics of particles inhaled in air or in helium-oxygen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10030764" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Effect of helium-oxygen on delivery of albuterol in a pediatric, volume-cycled, ventilated lung model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2670533" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Human lung deposition of particles suspended in air or in helium/oxygen mixture.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7589407" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Comparison of twenty three nebulizer/compressor combinations for domiciliary use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9155861" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Selecting and using nebuliser equipment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9743177" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Four hours of continuous albuterol nebulization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30837815" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Sterility and Stability Testing of Preservative-free Albuterol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32165556" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Continuous Albuterol With Benzalkonium in Children Hospitalized With Severe Asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Large-Volume, Preservative-Free Albuterol Concentrate</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30282664" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Safety and effectiveness of albuterol solutions with and without benzalkonium chloride when administered by continuous nebulization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32165555" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Benzalkonium Chloride in Albuterol Solutions: Time for a Change?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9149570" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Aerosol delivery during continuous nebulization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8595543" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Comparison of volume output from two different continuous nebulizer systems.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21122175" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : In-vitro comparison of 4 large-volume nebulizers in 8 hours of continuous nebulization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26070581" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Aerosol Therapy During Noninvasive Ventilation or High-Flow Nasal Cannula.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26196740" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Aerosol Therapy in Adults Receiving High Flow Nasal Cannula Oxygen Therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15165301" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : New frontiers in aerosol delivery during mechanical ventilation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18393813" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Advanced nebulizer designs employing vibrating mesh/aperture plate technologies for aerosol generation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20373905" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : In vitro characterization of the I-neb Adaptive Aerosol Delivery (AAD) system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20373904" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : The Adaptive Aerosol Delivery (AAD) technology: Past, present, and future.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20500093" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Omron NE U22: Comparison between vibrating mesh and jet nebulizer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28003554" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Reliability of Vibrating Mesh Technology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20459360" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Ultrasonic nebulization platforms for pulmonary drug delivery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19418954" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Aerosol devices and asthma therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14744267" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Performance comparison of nebulizer designs: constant-output, breath-enhanced, and dosimetric.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21333060" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Randomized controlled trial of a breath-actuated nebulizer in pediatric asthma patients in the emergency department.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15095329" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Facemasks and facial deposition of aerosols.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20923611" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Evaluation of droplet dispersion during non-invasive ventilation, oxygen therapy, nebuliser treatment and chest physiotherapy in clinical practice: implications for management of pandemic influenza and other airborne infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29017249" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Characterization of Aerosols Generated During Patient Care Activities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22563403" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Aerosol generating procedures and risk of transmission of acute respiratory infections to healthcare workers: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25224111" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Aerosol dispersion during various respiratory therapies: a risk assessment model of nosocomial infection to health care workers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25816216" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Aerosol transmission of infectious disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25816216" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Aerosol transmission of infectious disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25816216" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Aerosol transmission of infectious disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32543913" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Coughs and Sneezes: Their Role in Transmission of Respiratory Viral Infections, Including SARS-CoV-2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32783675" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Reducing Aerosol-Related Risk of Transmission in the Era of COVID-19: An Interim Guidance Endorsed by the International Society of Aerosols in Medicine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32783675" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Reducing Aerosol-Related Risk of Transmission in the Era of COVID-19: An Interim Guidance Endorsed by the International Society of Aerosols in Medicine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32783675" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Reducing Aerosol-Related Risk of Transmission in the Era of COVID-19: An Interim Guidance Endorsed by the International Society of Aerosols in Medicine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32783675" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Reducing Aerosol-Related Risk of Transmission in the Era of COVID-19: An Interim Guidance Endorsed by the International Society of Aerosols in Medicine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9149571" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : The choice of jet nebulizer, nebulizing flow, and addition of albuterol affects the output of tobramycin aerosols.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8996018" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : A comparison of pulmonary availability between Ventolin (albuterol) nebules and Ventolin (albuterol) Respirator Solution.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10205630" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Influence of formulation on jet nebulisation quality of alpha 1 protease inhibitor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12467504" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Liquid nebulization: emerging technologies conference summary.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16122399" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Assessing new technologies: patient-device interactions and deposition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20373913" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Intelligent nebulizers in the age of the Internet: The I-neb Adaptive Aerosol Delivery (AAD) system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30974049" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Improvements in Lung Function with Nebulized Revefenacin in the Treatment of Patients with Moderate to Very Severe COPD: Results from Two Replicate Phase III Clinical Trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30560478" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Revefenacin: First Global Approval.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30877642" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Amikacin Liposome Inhalation Suspension: A Review in Mycobacterium avium Complex Lung Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32797222" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14583926" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Continuous versus intermittent beta-agonists in the treatment of acute asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17218588" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Continuous bronchodilator therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17046476" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : A randomized, clinical trial comparing the efficacy of continuous nebulized albuterol (15 mg) versus continuous nebulized albuterol (15 mg) plus ipratropium bromide (2 mg) for the treatment of acute asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12114352" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Continuous vs intermittent beta-agonists in the treatment of acute adult asthma: a systematic review with meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26857949" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Effect of Nebulized Albuterol on Serum Lactate and Potassium in Healthy Subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16225712" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Albuterol delivery via tracheostomy tube.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28075193" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Workshop Report: Aerosol Delivery to Spontaneously Breathing Tracheostomized Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12029238" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Aerosol delivery during mechanical ventilation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12893644" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Aerosol delivery and modern mechanical ventilation: in vitro/in vivo evaluation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11094505" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Bronchodilator delivery with metered-dose inhaler during mechanical ventilation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18518831" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Aerosol delivery during mechanical ventilation: from basic techniques to new devices.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18440437" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : How best to deliver aerosol medications to mechanically ventilated patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20587095" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Influence of nebulizer type, position, and bias flow on aerosol drug delivery in simulated pediatric and adult lung models during mechanical ventilation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18518835" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Inhaled bronchodilator administration during mechanical ventilation: how to optimize it, and for which clinical benefit?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15165296" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Basic techniques for aerosol delivery during mechanical ventilation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20587094" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Evaluation of aerosol generator devices at 3 locations in humidified and non-humidified circuits during adult mechanical ventilation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18095891" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Pulmonary Drug Delivery System for inhalation therapy in mechanically ventilated patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17198046" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Inhalation therapy in invasive and noninvasive mechanical ventilation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22856594" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Inhalation therapy in patients receiving mechanical ventilation: an update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8756811" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Dose-response to bronchodilator delivered by metered-dose inhaler in ventilator-supported patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19796413" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Influence of moisture accumulation in inline spacer on delivery of aerosol using metered-dose inhaler during mechanical ventilation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12750882" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : In vitro evaluation of aerosol bronchodilator delivery during mechanical ventilation: pressure-control vs. volume control ventilation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9230718" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Inhaled bronchodilator therapy in mechanically ventilated patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11208634" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Improvement in aerosol delivery with helium-oxygen mixtures during mechanical ventilation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10390375" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Calibration of seven ICU ventilators for mechanical ventilation with helium-oxygen mixtures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10470772" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Effect of nitric oxide, perfluorocarbon, and heliox on minute volume measurement and ventilator volumes delivered.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11502662" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : The effect of helium on ventilator performance: study of five ventilators and a bedside Pitot tube spirometer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28270542" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Effects of Heat and Moisture Exchangers and Exhaled Humidity on Aerosol Deposition in a Simulated Ventilator-Dependent Adult Lung Model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23107173" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Albuterol delivery by 4 different nebulizers placed in 4 different positions in a pediatric ventilator in vitro model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10378564" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : A comparison of bronchodilator therapy delivered by nebulization and metered-dose inhaler in mechanically ventilated patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10926377" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : Bronchodilator therapy with metered-dose inhaler and spacer versus nebulizer in mechanically ventilated patients: comparison of magnitude and duration of response.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26070580" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : Aerosol Therapy in Pulmonary Critical Care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12441763" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : In vitro evaluation of aerosol bronchodilator delivery during noninvasive positive pressure ventilation: effect of ventilator settings and nebulizer position.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16318646" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : Albuterol delivery during noninvasive ventilation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17411410" id="rid139" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>140 : The mask for noninvasive ventilation: principles of design and effects on aerosol delivery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7486361" id="rid140" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>141 : Treatment of acute bronchospasm with beta-adrenergic agonist aerosols delivered by a nasal bilevel positive airway pressure circuit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22191396" id="rid141" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>142 : Aerosol therapy in patients receiving noninvasive positive pressure ventilation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11685304" id="rid142" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>143 : Salbutamol delivery during non-invasive mechanical ventilation in patients with chronic obstructive pulmonary disease: a randomized, controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26969671" id="rid143" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>144 : Use of high-flow nasal cannula oxygenation in ICU adults: a narrative review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27203510" id="rid144" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>145 : High-flow oxygen therapy and other inhaled therapies in intensive care units.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32807226" id="rid145" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>146 : A narrative review on trans-nasal pulmonary aerosol delivery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29261402" id="rid146" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>147 : Oral Versus Nasal High-Flow Bronchodilator Inhalation in Chronic Obstructive Pulmonary Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31473748" id="rid147" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>148 : Dose Response to Transnasal Pulmonary Administration of Bronchodilator Aerosols via Nasal High-Flow Therapy in Adults with Stable Chronic Obstructive Pulmonary Disease and Asthma.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
